<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Opioid treatment for opioid withdrawal in newborn infants - Zankl, A - 2021 | Cochrane Library</title> <meta content="Opioid treatment for opioid withdrawal in newborn infants - Zankl, A - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002059.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Opioid treatment for opioid withdrawal in newborn infants - Zankl, A - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002059.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002059.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Opioid treatment for opioid withdrawal in newborn infants" name="citation_title"/> <meta content="Angelika Zankl" name="citation_author"/> <meta content="angelika.zankl@gmail.com" name="citation_author_email"/> <meta content="Jill Martin" name="citation_author"/> <meta content="Royal Prince Alfred Hospital" name="citation_author_institution"/> <meta content="Jane G Davey" name="citation_author"/> <meta content="RPA Women and Babies, Royal Prince Alfred Hospital" name="citation_author_institution"/> <meta content="David A Osborn" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD002059.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/07/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002059.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002059.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002059.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Buprenorphine [therapeutic use]; Chlorpromazine [therapeutic use]; Clonidine [therapeutic use]; Diazepam [therapeutic use]; Hypnotics and Sedatives [therapeutic use]; Methadone [therapeutic use]; Morphine [therapeutic use]; Narcotics [*therapeutic use]; Neonatal Abstinence Syndrome [*drug therapy]; Opioid-Related Disorders [*drug therapy]; Opium [therapeutic use]; Phenobarbital [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002059.pub4&amp;doi=10.1002/14651858.CD002059.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002059\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002059\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa","fr","ms","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002059.pub4",title:"Opioid treatment for opioid withdrawal in newborn infants",firstPublishedDate:"Jul 7, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002059.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002059.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002059.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002059.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002059.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002059.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002059.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002059.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002059.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002059.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5262 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002059.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-sec-0126"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-sec-0112"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/appendices#CD002059-sec-0131"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/table_n/CD002059StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/table_n/CD002059StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Opioid treatment for opioid withdrawal in newborn infants</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information#CD002059-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Angelika Zankl</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information#CD002059-cr-0005">Jill Martin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information#CD002059-cr-0006">Jane G Davey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information#CD002059-cr-0007">David A Osborn</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information/en#CD002059-sec-0148">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 July 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002059.pub4">https://doi.org/10.1002/14651858.CD002059.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002059-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002059-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002059-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002059-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002059-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002059-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002059-abs-0001" lang="en"> <section id="CD002059-sec-0001"> <h3 class="title" id="CD002059-sec-0001">Background</h3> <p>Neonatal abstinence syndrome (NAS) due to opioid withdrawal may result in disruption of the mother‐infant relationship, sleep‐wake abnormalities, feeding difficulties, weight loss, seizures and neurodevelopmental problems. </p> </section> <section id="CD002059-sec-0002"> <h3 class="title" id="CD002059-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of using an opioid for treatment of NAS due to withdrawal from opioids in newborn infants. </p> </section> <section id="CD002059-sec-0003"> <h3 class="title" id="CD002059-sec-0003">Search methods</h3> <p>We ran an updated search on 17 September 2020 in CENTRAL via Cochrane Register of Studies Web and MEDLINE via Ovid. We also searched clinical trials databases, conference proceedings and the reference lists of retrieved articles for eligible trials. </p> </section> <section id="CD002059-sec-0004"> <h3 class="title" id="CD002059-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs), quasi‐ and cluster‐RCTs which enrolled infants born to mothers with opioid dependence and who were experiencing NAS requiring treatment with an opioid. </p> </section> <section id="CD002059-sec-0005"> <h3 class="title" id="CD002059-sec-0005">Data collection and analysis</h3> <p>Three review authors independently assessed trial eligibility and risk of bias, and independently extracted data. We used the GRADE approach to assess the certainty of evidence. </p> </section> <section id="CD002059-sec-0006"> <h3 class="title" id="CD002059-sec-0006">Main results</h3> <p>We included 16 trials (1110 infants) with NAS secondary to maternal opioid use in pregnancy. Seven studies at low risk of bias were included in sensitivity analysis. </p> <p><b>Opioid versus no treatment / usual care:</b> a single trial (80 infants) of morphine and supportive care versus supportive care alone reported no difference in treatment failure (risk ratio (RR) 1.29, 95% confidence interval (CI) 0.41 to 4.07; very low certainty evidence). No infant had a seizure. The trial did not report mortality, neurodevelopmental disability and adverse events. Morphine increased days hospitalisation (mean difference (MD) 15.00, 95% CI 8.86 to 21.14; very low certainty evidence) and treatment (MD 12.50, 95% CI 7.52 to 17.48; very low certainty evidence), but decreased days to regain birthweight (MD ‐2.80, 95% CI ‐5.33 to ‐0.27) and duration (minutes) of supportive care each day (MD ‐197.20, 95% CI ‐274.15 to ‐120.25). </p> <p><b>Morphine versus methadone:</b> there was no difference in treatment failure (RR 1.59, 95% CI 0.95 to 2.67; 2 studies, 147 infants; low certainty evidence). Seizures, neonatal or infant mortality and neurodevelopmental disability were not reported. A single study reported no difference in days hospitalisation (MD 1.40, 95% CI ‐3.08 to 5.88; 116 infants; low certainty evidence), whereas data from two studies found an increase in days treatment (MD 2.71, 95% CI 0.22 to 5.21; 147 infants; low certainty) for infants treated with morphine. A single study reported no difference in breastfeeding, adverse events, or out of home placement. </p> <p><b>Morphine versus sublingual buprenorphine:</b> there was no difference in treatment failure (RR 0.79, 95% CI 0.36 to 1.74; 3 studies, 113 infants; very low certainty evidence). Neonatal or infant mortality and neurodevelopmental disability were not reported. There was moderate certainty evidence of an increase in days hospitalisation (MD 11.45, 95% CI 5.89 to 17.01; 3 studies, 113 infants), and days treatment (MD 12.79, 95% CI 7.57 to 18.00; 3 studies, 112 infants) for infants treated with morphine. A single adverse event (seizure) was reported in infants exposed to buprenorphine. </p> <p><b>Morphine versus diluted tincture of opium (DTO):</b> a single study (33 infants) reported no difference in days hospitalisation, days treatment or weight gain (low certainty evidence). </p> <p><b>Opioid versus clonidine:</b> a single study (31 infants) reported no infant with treatment failure in either group. This study did not report seizures, neonatal or infant mortality and neurodevelopmental disability. There was low certainty evidence for no difference in days hospitalisation or days treatment. This study did not report adverse events. </p> <p><b>Opioid versus diazepam:</b> there was a reduction in treatment failure from use of an opioid (RR 0.43, 95% CI 0.23 to 0.80; 2 studies, 86 infants; low certainty evidence). Seizures, neonatal or infant mortality and neurodevelopmental disability were not reported. A single study of 34 infants comparing methadone versus diazepam reported no difference in days hospitalisation or days treatment (very low certainty evidence). Adverse events were not reported. </p> <p><b>Opioid versus phenobarbital:</b> there was a reduction in treatment failure from use of an opioid (RR 0.51, 95% CI 0.35 to 0.74; 6 studies, 458 infants; moderate certainty evidence). Subgroup analysis found a reduction in treatment failure in trials titrating morphine to ≧ 0.5 mg/kg/day (RR 0.21, 95% CI 0.10 to 0.45; 3 studies, 230 infants), whereas a single study using morphine &lt; 0.5 mg/kg/day reported no difference compared to use of phenobarbital (subgroup difference P = 0.05). Neonatal or infant mortality and neurodevelopmental disability were not reported. A single study (111 infants) of paregoric versus phenobarbital reported seven infants with seizures in the phenobarbital group, whereas no seizures were reported in two studies (170 infants) comparing morphine to phenobarbital. There was no difference in days hospitalisation or days treatment. A single study (96 infants) reported no adverse events in either group. </p> <p><b>Opioid versus chlorpromazine:</b> there was a reduction in treatment failure from use of morphine versus chlorpromazine (RR 0.08, 95% CI 0.01 to 0.62; 1 study, 90 infants; moderate certainty evidence). No seizures were reported in either group. There was low certainty evidence for no difference in days treatment. This trial reported no adverse events in either group. </p> <p>None of the included studies reported time to control of NAS. Data for duration and severity of NAS were limited, and we were unable to use these data in quantitative synthesis. </p> </section> <section id="CD002059-sec-0007"> <h3 class="title" id="CD002059-sec-0007">Authors' conclusions</h3> <p>Compared to supportive care alone, the addition of an opioid may increase duration of hospitalisation and treatment, but may reduce days to regain birthweight and the duration of supportive care each day. Use of an opioid may reduce treatment failure compared to phenobarbital, diazepam or chlorpromazine. Use of an opioid may have little or no effect on duration of hospitalisation or treatment compared to use of phenobarbital, diazepam or chlorpromazine. The type of opioid used may have little or no effect on the treatment failure rate. Use of buprenorphine probably reduces duration of hospitalisation and treatment compared to morphine, but there are no data for time to control NAS with buprenorphine, and insufficient evidence to determine safety. There is insufficient evidence to determine the effectiveness and safety of clonidine. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002059-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002059-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002059-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002059-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002059-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002059-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002059-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002059-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002059-abs-0002" lang="en"> <h3>Opioid treatment for opioid withdrawal in newborn infants</h3> <p><b>Review question</b> </p> <p>To determine the efficacy and safety of using an opioid as compared to a sedative or non‐pharmacological treatment for the treatment of neonatal abstinence syndrome (NAS) due to withdrawal from opioids. </p> <p><b>Background</b> </p> <p>Use of opioids (prescribed or illicit) by pregnant women may result in their newborn infant experiencing withdrawal symptoms, collectively referred to as neonatal abstinence syndrome (NAS). These symptoms may result in disruption of the mother‐infant relationship, sleeping and feeding difficulties, weight loss and seizures. Treatments for newborn infants that are used to ameliorate NAS and reduce complications include supportive care treatments (such as a pacifier, swaddling, close wrapping, small frequent feeds, close skin contact by carrying in a sling, and other methods), prescription of opioids or sedatives, or both. </p> <p><b>Study characteristics</b> </p> <p>The evidence in this Cochrane Review is current to September 2020.</p> <p><b>Key results</b> </p> <p>We included 16 studies involving 1110 infants with withdrawal symptoms as a result of their mothers’ use of opioids whilst pregnant. Eleven of the 16 included studies have taken place in the USA. Australia, Germany, Iran, Scotland and Switzerland contributed one study each. We considered seven studies likely to produce reliable results (at low risk of bias). All studies were relatively small and most included infants of mothers using opioids as well as other drugs of dependence. Some of the formulations used to treat the infants in the included studies do not meet regulatory guidance for safety in infants. </p> <p>There is insufficient evidence to determine the effectiveness and safety of non‐pharmacological interventions alone compared to non‐pharmacological interventions plus a pharmacological agent (drug such as opioid or sedative) for treatment of NAS. A single trial reported that the addition of an opioid (morphine) to supportive treatments, compared to supportive treatments alone, increased duration of hospitalisation and treatment, but reduced the number of days to regain birthweight and the duration of supportive care each day. </p> <p>Evidence from six trials found that the use of an opioid may reduce treatment failure rate, compared to the use of the sedatives phenobarbital or diazepam. Treatment failure means failure to achieve control of symptoms, defined as a failure to reduce a standardised score of NAS from a clinically significant level to a clinically 'safe' level. In addition, evidence from these six trials showed that the use of an opioid may have little or no effect on the duration of hospitalisation or treatment compared to the use of the sedatives phenobarbital or diazepam. There was little or no difference in treatment failure according to the type of opioid used (morphine, methadone or buprenorphine). However, use of the opioid buprenorphine probably reduces the duration of hospitalisation and duration of treatment compared to morphine. There is insufficient evidence to determine the effectiveness and safety of clonidine, a sedative. </p> <p>We identified six ongoing studies and four studies awaiting classification, whose results have not been included in this review. </p> <p><b>Certainty of evidence</b> </p> <p>The certainty of the evidence was low to very low for the majority of outcomes reported. There is moderate certainty that treatment failure is reduced by the use of an opioid compared to the use of the sedatives phenobarbital or chlorpromazine. There is moderate certainty that the use of sublingual (under the tongue) buprenorphine reduces duration of treatment and hospitalisation compared to the use of morphine. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002059-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002059-sec-0126"></div> <h3 class="title" id="CD002059-sec-0127">Implications for practice</h3> <section id="CD002059-sec-0127"> <p>The addition of an opioid to supportive care may increase duration of hospitalisation and treatment, but may reduce days to regain birthweight and duration of supportive care each day compared to supportive care alone. However, mortality, neurodevelopment and adverse events were not reported. </p> <p>The use of an opioid reduces treatment failure compared to phenobarbital, diazepam or chlorpromazine. Use of an opioid may have little or no effect on duration of hospitalisation or treatment compared to use of phenobarbital, diazepam or chlorpromazine. However, mortality, neurodevelopment and adverse events were either not reported or studies were too small to detect adverse events. </p> <p>We are uncertain if type of opioid used affects treatment failure rate. Use of buprenorphine probably reduces duration of hospitalisation and treatment compared to morphine, but there are no data for time to control NAS. Seizures, mortality, neurodevelopment and adverse events were either not reported or studies were too small to detect seizures or adverse events. There is insufficient evidence to determine the effectiveness and safety of clonidine. </p> </section> <h3 class="title" id="CD002059-sec-0128">Implications for research</h3> <section id="CD002059-sec-0128"> <p>There are six ongoing studies and four awaiting classification which may affect the findings of this review. </p> <p>Trials of non‐pharmacological interventions for reducing separation of mother and infant, admission to the nursery and pharmacological treatment of NAS are needed. </p> <p>Trials of higher versus lower threshold for initiation of pharmacological intervention based on validated assessments of NAS severity are needed. </p> <p>Trials to determine optimal dosing strategies (dose and timing) of specific opioids including morphine, methadone and sublingual buprenorphine are needed. Dose escalation studies should assess time to control of NAS (control of symptoms or reduction of NAS score to a clinically 'safe' level), severity and duration of withdrawal, infant feeding, weight loss and gain, and adverse effects including oversedation. </p> <p>Trials comparing different opioids with excipients appropriate for use in newborn infants are needed. Specifically, use of oral morphine compared to oral methadone and compared to sublingual buprenorphine. </p> <p>Future trials should measure the outcomes prespecified in this review, and be powered to detect important adverse events, including seizures, oversedation and infant mortality. Trials are needed that measure psychosocial (mother‐infant interaction, out of home care), growth and neurodevelopmental outcomes using validated scales of infant development. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002059-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002059-sec-0008"></div> <div class="table" id="CD002059-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Opioid versus placebo or no treatment / usual care for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus placebo or no treatment / usual care for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, Australia<br/><b>Intervention:</b> opioid versus placebo or no treatment / usual care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine and usual care</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/>(48 to 479) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> <br/>(0.41 to 4.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>14</b> days in the usual care group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>15 higher</b> (8.86 to 21.14 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>8.5</b> days in the usual care group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>12.5 higher</b> (7.52 to 17.48 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment‐related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious risk of bias (quasi‐random allocation, no blinding).<br/><sup>b</sup>Downgraded one level for serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002059-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Morphine versus methadone for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morphine versus methadone for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> morphine versus methadone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Methadone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>219 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b><br/>(208 to 585) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.59</b> <br/>(0.95 to 2.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>21.8</b> in the methadone group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>1.4 higher</b> (3.08 lower to 5.88 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>14 to 14.7</b> in the methadone group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>2.71 higher</b> (0.22 to 5.21 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(0 to 138) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 8.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single event only</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals).<br/><sup>b</sup>Downgraded one level for serious inconsistency (moderate heterogeneity: I² = 54%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002059-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Morphine versus buprenorphine for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morphine versus buprenorphine for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> morphine versus buprenorphine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine versus buprenorphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b><br/>(74 to 360) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> <br/>(0.36 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buprenorphine dose commenced at 13.2 μg/kg/day with dose titration to a maximum of 39 μg/kg/day in one trial, and commenced at 15.9 μg/kg/day with dose titration to a maximum of 60 μg/kg/day in two trials. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(0 to 129) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 7.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single event only</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>21 to 32</b> in the buprenorphine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>11.45 higher</b> (5.89 to 17.01 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>15 to 23</b> in the buprenorphine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>12.79 higher</b> (7.57 to 18 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment‐related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(0 to 129) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 7.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single event only</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (two studies unblinded).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals).<br/><sup>c</sup>Downgraded one level for serious inconsistency (heterogeneity I² = 42%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002059-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Morphine versus dilute tincture of opium for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morphine versus dilute tincture of opium for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, Germany<br/><b>Intervention:</b> morphine versus dilute tincture of opium </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dilute tincture of opium (DTO)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>32.4</b> in the DTO group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>5.1 higher</b> (2.08 lower to 12.28 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>26.9</b> in the DTO group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>2.9 higher</b> (5.22 lower to 11.02 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> (treatment related) </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002059-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Opioid versus clonidine for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus clonidine for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> opioid versus clonidine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Clonidine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>14.9</b> in the clonidine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>6.1 higher</b> (0.78 lower to 12.98 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>32</b> in the clonidine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>10.7 higher</b> (2.76 lower to 24.16 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals, single small study). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002059-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Opioid versus diazepam for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus diazepam for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> opioid versus diazepam </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Diazepam</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Opioid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b><br/>(89 to 311) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/>(0.23 to 0.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a, b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Differences in study methodology and type of opioid used: one study paregoric versus diazepam; one study methadone versus diazepam. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>16.8</b> in the diazepam group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>4.38 higher</b> (1.26 lower to 10.02 higher) in the opioid group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methadone versus diazepam</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>10.2</b> in the diazepam group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>1.56 higher</b> (1.59 lower to 4.71 higher) in the opioid group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methadone versus diazepam</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (high risk allocation procedures, unblinded studies).<br/><sup>b</sup>Downgraded one level for serious inconsistency (heterogeneity I² = 37%).<br/><sup>c</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002059-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Opioid versus phenobarbital for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus phenobarbital for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, Australia, Iran, Switzerland, USA<br/><b>Intervention:</b> opioid versus phenobarbital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Opioid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b><br/>(102 to 215) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b> <br/>(0.35 to 0.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test for subgroup differences according to type of opioid use (morphine, paregoric or methadone) not significant. </p> <p>Subgroup analysis of morphine versus phenobarbital found significant reduction in treatment failure (RR 0.46, 95% CI 0.30 to 0.73; I<sup>2</sup> = 44%; 4 studies, 299 infants). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b><br/>(0 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b> <br/>(0 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b, c, d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study reported seven infants with seizures in phenobarbital group. The other study reported no events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation ranged from <b>12.5 to 34.8</b> in the phenobarbital group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation in the opioid group was <b>0.62 lower</b> (2.97 lower to 1.74 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d, e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment ranged from <b>8.5 to 32</b> in the phenobarbital group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment in the opioid group was <b>1.01 higher</b> (0.48 lower to 2.5 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b, d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d, e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious inconsistency (heterogeneity I² = 32%).<br/><sup>b</sup>Downgraded one level for serious risk of bias (single study at low risk of bias).<br/><sup>c</sup>Downgraded one level for serious inconsistency (one of two studies reported events).<br/><sup>d</sup>Downgraded one level for serious imprecision (wide confidence intervals).<br/><sup>e</sup>Downgraded one level for very serious risk of bias (no study at low risk of bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002059-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Opioid versus chlorpromazine for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus chlorpromazine for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, Switzerland<br/><b>Intervention:</b> morphine versus chlorpromazine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Chlorpromazine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>277 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(3 to 171) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b> <br/>(0.01 to 0.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean was 25 days treatment in the chlorpromazine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment in the morphine group was <b>3 lower</b> (15.12 lower to 9.12 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded for serious risk of bias and imprecision.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious imprecision. Single small study.<br/><sup>b</sup>Downgraded two levels for serious imprecision. Single small study with no events.<br/><sup>c</sup>Downgraded two levels for serious risk of attrition bias and imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002059-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002059-sec-0009"></div> <section id="CD002059-sec-0010"> <h3 class="title" id="CD002059-sec-0010">Description of the condition</h3> <p>Opioid use in pregnancy and neonatal abstinence syndrome (NAS) due to opioid withdrawal are currently significant clinical and social problems. Since the previous Cochrane Review updates on this topic (<a href="./references#CD002059-bbs2-0169" title="OsbornDA , ColeMJ , JefferyHE . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD002059. [DOI: 10.1002/14651858.CD002059]">Osborn 2002</a>; <a href="./references#CD002059-bbs2-0170" title="OsbornDA , JefferyHE , ColeMJ . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002059. [DOI: 10.1002/14651858.CD002059.pub2]">Osborn 2005</a>; <a href="./references#CD002059-bbs2-0171" title="OsbornDA , JefferyHE , ColeM . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD002059. [DOI: 10.1002/14651858.CD002059.pub3]">Osborn 2010</a>), rates of illicit drug use by pregnant women in the USA, as reported by the National Household Survey on Drug Abuse, have increased from 3.4% in 1999 to 5.4% in 2013, with heroin abuse still being the most common (<a href="./references#CD002059-bbs2-0142" title="Office of Applied Statistics, Substance Abuse and Mental Health Administration (SAMHSA). National household survey on drug abuse. 1999. www.datafiles.samhsa.gov/study/national-household-survey-drug-abuse-nhsda-1999-nid13544 2013. Accessed 28th January 2021.">SAMHSA 1999</a>; <a href="./references#CD002059-bbs2-0143" title="Office of Applied Statistics, Substance Abuse and Mental Health Administration (SAMHSA). National household survey on drug abuse. 2013. https://www.aihw.gov.au/reports/illicit-use-of-drugs/ndshs-2013-detailed/contents/table-of-contents 25 November 2014. Accessed 28th January 2021.">SAMHSA 2013</a>). Prescription of methadone and buprenorphine are standard maintenance treatments for pregnant women with an opioid addiction (<a href="./references#CD002059-bbs2-0086" title="BroglySB , SaiaKA , WalleyAY , DuHM , SebastianiP . Prenatal buprenorphine verses methadone exposure and neonatal outcomes: systematic review and meta-analysis. American Journal of Epidemiology2014;180(7):673-86. [DOI: 10.1093/aje/kwu190] [PMID: 25150272]">Brogly 2014</a>; <a href="./references#CD002059-bbs2-0089" title="CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehaviour effects following buprenorphine verses methadone exposure. Addiction2012;107(Suppl 1(0 1)):63-73. [DOI: 10.1111/j.1360-0443.2012.04040.x] [PMID: 23106928]">Coyle 2012</a>; <a href="./references#CD002059-bbs2-0107" title="JonesHE , KaltenbachK , HeilSH , StineMD , CoyleMD , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363(24):2320-31. [DOI: 10.1056/NEJMoa1005359] [PMID: 21142534]">Jones 2010</a>; <a href="./references#CD002059-bbs2-0116" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-e61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>; <a href="./references#CD002059-bbs2-0146" title="SiuA , RobinsonCA . Neonatal abstinence syndrome: essentials for the practitioner. Journal of Pediatric Pharmacology and Therapeutics2014;19(3):147-55. [DOI: 10.5863/1551-6776-19.3.147] [PMID: 25309144]">Siu 2014</a>). Of growing concern is the use and abuse of prescription opioid analgesic medications by pregnant women for non‐cancer related pain (<a href="./references#CD002059-bbs2-0116" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-e61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>; <a href="./references#CD002059-bbs2-0117" title="KraftWK , StoverNW , DavisJM . Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Seminars in Perinatology2016;40(3):203-12. [DOI: 10.1053/j.semperi.2015.12.007] [PMID: 26791055]">Kraft 2016</a>; <a href="./references#CD002059-bbs2-0137" title="PatrickSW , DudleyJ , MartinPR , HarrellFE , WarrenMD , HartmannKE , et al. Prescription opioid epidemic and infant outcomes. Pediatrics2015;135(5):842-50. [PMID: 10.1542/peds.2014-3299] [PMID: 25869370]">Patrick 2015</a>; <a href="./references#CD002059-bbs2-0148" title="StoverMW , DavisJM . Opioids in pregnancy and neonatal abstinence syndrome. Seminars in Perinatology2015;39(7):561-5. [DOI: 10.1053/j.semperi.2015.08.013] [PMID: 26452318]">Stover 2015</a>). The flow‐on effect of the illicit and prescribed opioid usage rates across the USA by pregnant women is a nationwide increase in admission of newborn infants to neonatal intensive care units (NICUs) for NAS from 0.6% (7 cases per 1000) in 2004 to 4.0% (27 cases per 1000) in 2013 (<a href="./references#CD002059-bbs2-0153" title="ToliaVN , PatrickSW , BennettMM , MurthyK , SousaJ , SmithPB , et al. Increasing incidence of the neonatal abstinence syndrome in US neonatal ICUs. New England Journal of Medicine2015;372(22):2118-26. [DOI: 10.1056/NEJMsa1500439] [PMID: 25913111]">Tolia 2015</a>). As the reported average length of stay for infants requiring treatment for NAS in the USA is 16 days, cost estimates of treatment are USD 159,000 to USD 238,000 greater than for healthy infant counterparts (<a href="./references#CD002059-bbs2-0139" title="PeltzG , AnandKJ . Long-acting opioids for treating neonatal abstinence syndrome: a high price for a short stay?JAMA2015;314(19):2023-4. [DOI: 10.1001/jama.2015.13537] [PMID: 26469386]">Peltz 2015</a>). These data are reflected outside the USA across several European countries, Canada, England and Australia (<a href="./references#CD002059-bbs2-0080" title="AllegaertK , Van der AnkerJN . Neonatal withdrawal syndrome: reaching epidemic proportions across the globe. Archives of Diseases in Childhood. Fetal and Neonatal Edition2016;10(1):F2-3. [DOI: 10.1136/archdischild-2015-309566] [PMID: 26482412]">Allegaert 2016</a>; <a href="./references#CD002059-bbs2-0083" title="BauchingerS , SapetschnigI , DandaM , SommerC , ReschB , UrlesbergerB , et al. Methods in neonatal abstinence syndrome (NAS): results of a nationwide survey in Austria. Z Geburtshilfe Neonatology2015;219(4):185-189. [10.1055/s-0035-1545289] [PMID: 26039498]">Bauchinger 2015</a>; <a href="./references#CD002059-bbs2-0087" title="BroglySB , TurnerS , LajkoszK , DaviesG , NewmanA , JohnsonA , et al. Infants born to opioid-dependent women in Ontario, 2002-2014. Journal of Obstetrics and Gynaecology Canada2017;39(3):157-65. [DOI: 10.1016/j.jogc.2016.11.009] [PMID: 28343557]">Brogly 2017</a>; <a href="./references#CD002059-bbs2-0091" title="DaviesH , GilbertR , JohnsonK , PetersenI , NazarethI , O'DonnellM , et al. Neonatal drug withdrawal syndrome: cross country comparison using hospital administrative data in England, the USA, Western Australia and Ontario, Canada. Archives of Diseases in Childhood. Fetal and Neonatal Edition2016;101(1):F26-30. [DOI: 10.1136/archdischild-2015-308948] [PMID: 26290479]">Davies 2016</a>; <a href="./references#CD002059-bbs2-0115" title="KirchnerL , Graf-RohmeisterK , Klebermass-SchrehofK , WeningerM , JagschR , MetzV , et al. Neonatal abstinence syndrome in European and North American neonates: differences in clinical characteristics derived from a prospective randomized trial. Klinische Pädiatrie2014;226(5):274-80. [DOI: 10.1055/s-0034-1372586] [PMID: 25062111]">Kirchner 2014</a>; <a href="./references#CD002059-bbs2-0079" title="Australian Institute of Health and Welfare. National Drug Strategy Household Survey detailed report 2013; November 2014. Available at www.aihw.gov.au/getmedia/c2e94ca2-7ce8-496f-a765-94c55c774d2b/16835_1.pdf.aspx?inline=true.">AIHW 2013</a>; <a href="./references#CD002059-bbs2-0154" title="TurnerSD , GomesT , CamachoX , YaoZ , GuittmannA , MamdaniMM , et al. Neonatal opioid withdrawal and antenatal prescribing. CMAJ Open2015;3(1):E55-61. [DOI: 10.9778/cmajo.20140065] [PMID: 25844370]">Turner 2015</a>; <a href="./references#CD002059-bbs2-0155" title="UngerA , MetzV , FischerG . Opioid dependent and pregnant: what are the best options for mothers and neonates?Obstetrics and Gynecology International2012;2012:195954. [DOI: 10.1155/2012/195954] [PMID: 22496696]">Unger 2012</a>), indicating that NAS is a globally significant clinical and social problem with concomitant fiscal burdens for healthcare providers. Such is the global concern that the World Health Organization (WHO) has published guidelines for clinicians regarding the management of substance use in pregnancy and NAS (<a href="./references#CD002059-bbs2-0163" title="World Health Organization. Guidelines for the identification and management of substance use and substance use disorders in pregnancy; 2014. Available at www.who.int/iris/bitstream/10665/107130/1/9789241548731_eng.pdf.">WHO 2014</a>). </p> <p>Between 48% and 94% of infants exposed to opioids in utero develop clinical signs of withdrawal, with signs of withdrawal from methadone being more common than from heroin (<a href="./references#CD002059-bbs2-0018" title="AlroomiLG , DavidsonJ , EvansTJ , GaleaP , HowatR . Maternal narcotic abuse and the newborn. Archives of Disease in Childhood1988;63(1):81-3. [DOI: 10.1136/adc.63.1.81] [PMID: 3348657]">Alroomi 1988</a>; <a href="./references#CD002059-bbs2-0026" title="DoberczakTM , KandallSR , WiletsI . Neonatal opiate abstinence syndrome in term and preterm infants. Journal of Pediatrics1991;118(6):933-7. [DOI: 10.1016/s0022-3476(05)82214-0] [PMID: 2040931]">Doberczak 1991</a>; <a href="./references#CD002059-bbs2-0096" title="FrickerHS , SegalS . Narcotic addiction, pregnancy, and the newborn. American Journal of Diseases of Children1978;132(4):360-6. [DOI: 10.1001/archpedi.1978.02120290032004] [PMID: 645651]">Fricker 1978</a>; <a href="./references#CD002059-bbs2-0118" title="LamSK , ToWK , DuthieSJ , MaHK . Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1992;32(3):216-21. [DOI: 10.1111/j.1479-828x.1992.tb01950.x] [PMID: 1445130]">Lam 1992</a>; <a href="./references#CD002059-bbs2-0121" title="MaasU , KattnerE , Weingart JesseB , SchaferA , ObladenM . Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. Journal of Perinatal Medicine1990;18(2):111-8. [DOI: 10.1515/jpme.1990.18.2.111] [PMID: 2366131]">Maas 1990</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0132" title="OlofssonM , BuckleyW , AndersenGE , Friis HansenB . Investigation of 89 children born by drug-dependent mothers. I. Neonatal course. Acta Paediatrica Scandinavica1983;72(3):403-6. [DOI: 10.1111/j.1651-2227.1983.tb09736.x] [PMID: 6880727]">Olofsson 1983</a>; <a href="./references#CD002059-bbs2-0054" title="OstreaEM , ChavezCJ , StraussME . A study of factors that influence the severity of neonatal narcotic withdrawal. Journal of Pediatrics1976;88(4 Pt 1):642-5. [DOI: 10.1016/s0022-3476(76)80027-3] [PMID: 1255327]">Ostrea 1976</a>). Onset of NAS in the case of heroin withdrawal is usually within 24 hours after birth and has a shorter (8 to 10 days) and milder manifestation of clinical symptoms (<a href="./references#CD002059-bbs2-0018" title="AlroomiLG , DavidsonJ , EvansTJ , GaleaP , HowatR . Maternal narcotic abuse and the newborn. Archives of Disease in Childhood1988;63(1):81-3. [DOI: 10.1136/adc.63.1.81] [PMID: 3348657]">Alroomi 1988</a>; <a href="./references#CD002059-bbs2-0084" title="BellGL , LauK . Perinatal and neonatal issues of substance abuse. Pediatric Clinics of North America1995;42(2):261-81. [DOI: 10.1016/s0031-3955(16)38946-5] [PMID: 7536914]">Bell 1995</a>; <a href="./references#CD002059-bbs2-0116" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-e61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>; <a href="./references#CD002059-bbs2-0146" title="SiuA , RobinsonCA . Neonatal abstinence syndrome: essentials for the practitioner. Journal of Pediatric Pharmacology and Therapeutics2014;19(3):147-55. [DOI: 10.5863/1551-6776-19.3.147] [PMID: 25309144]">Siu 2014</a>). Conversely, withdrawal from methadone or buprenorphine has a usual onset of NAS from 48 to 72 hours after birth, with a more protracted (up to 30 days or more) and more pronounced manifestation of clinical symptoms (<a href="./references#CD002059-bbs2-0018" title="AlroomiLG , DavidsonJ , EvansTJ , GaleaP , HowatR . Maternal narcotic abuse and the newborn. Archives of Disease in Childhood1988;63(1):81-3. [DOI: 10.1136/adc.63.1.81] [PMID: 3348657]">Alroomi 1988</a>; <a href="./references#CD002059-bbs2-0086" title="BroglySB , SaiaKA , WalleyAY , DuHM , SebastianiP . Prenatal buprenorphine verses methadone exposure and neonatal outcomes: systematic review and meta-analysis. American Journal of Epidemiology2014;180(7):673-86. [DOI: 10.1093/aje/kwu190] [PMID: 25150272]">Brogly 2014</a>; <a href="./references#CD002059-bbs2-0089" title="CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehaviour effects following buprenorphine verses methadone exposure. Addiction2012;107(Suppl 1(0 1)):63-73. [DOI: 10.1111/j.1360-0443.2012.04040.x] [PMID: 23106928]">Coyle 2012</a>; <a href="./references#CD002059-bbs2-0026" title="DoberczakTM , KandallSR , WiletsI . Neonatal opiate abstinence syndrome in term and preterm infants. Journal of Pediatrics1991;118(6):933-7. [DOI: 10.1016/s0022-3476(05)82214-0] [PMID: 2040931]">Doberczak 1991</a>; <a href="./references#CD002059-bbs2-0096" title="FrickerHS , SegalS . Narcotic addiction, pregnancy, and the newborn. American Journal of Diseases of Children1978;132(4):360-6. [DOI: 10.1001/archpedi.1978.02120290032004] [PMID: 645651]">Fricker 1978</a>; <a href="./references#CD002059-bbs2-0107" title="JonesHE , KaltenbachK , HeilSH , StineMD , CoyleMD , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363(24):2320-31. [DOI: 10.1056/NEJMoa1005359] [PMID: 21142534]">Jones 2010</a>; <a href="./references#CD002059-bbs2-0116" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-e61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>; <a href="./references#CD002059-bbs2-0118" title="LamSK , ToWK , DuthieSJ , MaHK . Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1992;32(3):216-21. [DOI: 10.1111/j.1479-828x.1992.tb01950.x] [PMID: 1445130]">Lam 1992</a>; <a href="./references#CD002059-bbs2-0121" title="MaasU , KattnerE , Weingart JesseB , SchaferA , ObladenM . Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. Journal of Perinatal Medicine1990;18(2):111-8. [DOI: 10.1515/jpme.1990.18.2.111] [PMID: 2366131]">Maas 1990</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0132" title="OlofssonM , BuckleyW , AndersenGE , Friis HansenB . Investigation of 89 children born by drug-dependent mothers. I. Neonatal course. Acta Paediatrica Scandinavica1983;72(3):403-6. [DOI: 10.1111/j.1651-2227.1983.tb09736.x] [PMID: 6880727]">Olofsson 1983</a>; <a href="./references#CD002059-bbs2-0054" title="OstreaEM , ChavezCJ , StraussME . A study of factors that influence the severity of neonatal narcotic withdrawal. Journal of Pediatrics1976;88(4 Pt 1):642-5. [DOI: 10.1016/s0022-3476(76)80027-3] [PMID: 1255327]">Ostrea 1976</a>). Although there is some evidence to correlate methadone dose and severity of withdrawal (<a href="./references#CD002059-bbs2-0090" title="DasheJS , SheffieldJS , OlscherDA , ToddSJ , JacksonGL , Wendel GD Jr. Relationship between maternal methadone dosage and neonatal withdrawal. Obstetrics and Gynecology2002;100(6):1244-9. [DOI: 10.1016/s0029-7844(02)02387-6] [PMID: 12468169]">Dashe 2002</a>; <a href="./references#CD002059-bbs2-0026" title="DoberczakTM , KandallSR , WiletsI . Neonatal opiate abstinence syndrome in term and preterm infants. Journal of Pediatrics1991;118(6):933-7. [DOI: 10.1016/s0022-3476(05)82214-0] [PMID: 2040931]">Doberczak 1991</a>; <a href="./references#CD002059-bbs2-0039" title="HarperRG , SolishG , FeingoldE , Gersten WoolfNB , SokalMM . Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. American Journal of Obstetrics and Gynecology1977;129:417-24. [DOI: 10.1016/0002-9378(77)90588-9] [PMID: 910821]">Harper 1977</a>; <a href="./references#CD002059-bbs2-0054" title="OstreaEM , ChavezCJ , StraussME . A study of factors that influence the severity of neonatal narcotic withdrawal. Journal of Pediatrics1976;88(4 Pt 1):642-5. [DOI: 10.1016/s0022-3476(76)80027-3] [PMID: 1255327]">Ostrea 1976</a>), clinically significant manifestations of NAS are uncommon when the dose is below 20 mg/day (<a href="./references#CD002059-bbs2-0149" title="StraussME , AndreskoM , StrykerJC , WardellJN . Relationship of neonatal withdrawal to maternal methadone dose. American Journal of Drug and Alcohol Abuse1976;3(2):339-45. [DOI: 10.3109/00952997609077202] [PMID: 1032747]">Strauss 1976</a>). The association between methadone dose in pregnancy and subsequent development of NAS is inconsistent (<a href="./references#CD002059-bbs2-0088" title="ClearyBJ , DonnellyJ , StrawbridgeJ , GallagherPJ , FaheyT , ClarkeM , et al. Methadone dose and neonatal abstinence syndrome - systematic review and meta-analysis. Addiction2010;105(12):2017-84. [DOI: 10.1111/j.1360-0443.2010.03120.x] [PMID: 20840198]">Cleary 2010</a>). There is some evidence that prenatal maintenance treatment with buprenorphine may reduce the severity of NAS and length of hospital stay compared to methadone (<a href="./references#CD002059-bbs2-0086" title="BroglySB , SaiaKA , WalleyAY , DuHM , SebastianiP . Prenatal buprenorphine verses methadone exposure and neonatal outcomes: systematic review and meta-analysis. American Journal of Epidemiology2014;180(7):673-86. [DOI: 10.1093/aje/kwu190] [PMID: 25150272]">Brogly 2014</a>; <a href="./references#CD002059-bbs2-0089" title="CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehaviour effects following buprenorphine verses methadone exposure. Addiction2012;107(Suppl 1(0 1)):63-73. [DOI: 10.1111/j.1360-0443.2012.04040.x] [PMID: 23106928]">Coyle 2012</a>; <a href="./references#CD002059-bbs2-0107" title="JonesHE , KaltenbachK , HeilSH , StineMD , CoyleMD , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363(24):2320-31. [DOI: 10.1056/NEJMoa1005359] [PMID: 21142534]">Jones 2010</a>; <a href="./references#CD002059-bbs2-0110" title="KaltenbachK , HolbrookA , CoyleMG , HeilSH , SalisburyA , StineS , et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction2012;107(Suppl 1(0 1):45-52. [DOI: 10.1111/j.1360-0443.2012.04038.x] [PMID: 23106926]">Kaltenbach 2012</a>). However, polydrug use in pregnant women on maintenance buprenorphine has been reported to confound subsequent treatment of NAS in infants born to those women (<a href="./references#CD002059-bbs2-0136" title="PatelP , Abdel-LatifME , HazeltonB , WodakA , ChenJ , EmsleyF , et al. Perinatal outcomes of Australian buprenorphine-exposed mothers and their newborn infants. Journal of Paediatric and Child Health2013;49(9):746-53. [DOI: 10.1111/jpc.12264] [PMID: 23745982]">Patel 2013</a>). </p> <p>The clinical presentation of NAS may involve central nervous system (CNS) signs including tremors, irritability, increased wakefulness, high‐pitched crying, increased muscle tone, hyperactive deep tendon reflexes, exaggerated Moro reflex, seizures, frequent yawning and sneezing, poor feeding, and uncoordinated and constant sucking; gastrointestinal signs including vomiting, diarrhoea, dehydration, and poor weight gain; and autonomic signs including increased sweating, nasal stuffiness, fever, mottling and temperature instability (<a href="./references#CD002059-bbs2-0078" title="HudakML , TanRC , Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics2012;129(2):e540-60. [DOI: 10.1542/peds.2011-3212] [PMID: 22291123]">AAP 2012</a>). Seizures occur in 2% to 11% of infants withdrawing from opioids (<a href="./references#CD002059-bbs2-0026" title="DoberczakTM , KandallSR , WiletsI . Neonatal opiate abstinence syndrome in term and preterm infants. Journal of Pediatrics1991;118(6):933-7. [DOI: 10.1016/s0022-3476(05)82214-0] [PMID: 2040931]">Doberczak 1991</a>; <a href="./references#CD002059-bbs2-0040" title="HerzlingerRA , KandallSR , Vaughan HG Jr. Neonatal seizures associated with narcotic withdrawal. Journal of Pediatrics1977;91(4):638-41. [DOI: 10.1016/s0022-3476(77)80523-4] [PMID: 908988]">Herzlinger 1977</a>; <a href="./references#CD002059-bbs2-0043" title="KandallSR , AlbinS , GartnerLM , LeeKS , EidelmanA , LowinsonJ . The narcotic-dependent mother: fetal and neonatal consequences. Early Human Development1977;1(2):159-69. [DOI: 10.1016/0378-3782(77)90017-2] [PMID: 617308]">Kandall 1977</a>), and may be more common with methadone than heroin withdrawal (<a href="./references#CD002059-bbs2-0040" title="HerzlingerRA , KandallSR , Vaughan HG Jr. Neonatal seizures associated with narcotic withdrawal. Journal of Pediatrics1977;91(4):638-41. [DOI: 10.1016/s0022-3476(77)80523-4] [PMID: 908988]">Herzlinger 1977</a>). However, benign myoclonus is also common in infants with NAS from opioids and associated with a normal electroencephalogram (EEG) (<a href="./references#CD002059-bbs2-0100" title="Held-EgliK , RueggerC , Das-KunduS , SchmittB , BucherHU . Benign neonatal sleep myoclonus in newborn infants of opioid dependent mothers. Acta Paediatrica2009;98:69-73. [DOI: 10.1111/j.1651-2227.2008.01010.x] [PMID: 18803624]">Held‐Egli 2009</a>). </p> <p>In human studies, exposure to opioids in utero has been reported to reduce fetal growth parameters and lower birth weights (<a href="./references#CD002059-bbs2-0095" title="FinneganLP , KandallSR . Maternal and neonatal effects of alcohol and drugs. In: LowinsonJH , RuizP , MillmanRB , LangrodJG , editors(s). Substance Abuse: A Comprehensive Textbook. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2005:805-39.">Finnegan 2005</a>; <a href="./references#CD002059-bbs2-0111" title="KandallSR , AlbinS , LowinsonJ , BerleB , EidelmanAI , GartnerLM . Differential effects of maternal heroin and methadone use on birthweight. Pediatrics1976;58(5):681-5. [PMID: 980601]">Kandall 1976</a>; <a href="./references#CD002059-bbs2-0114" title="KennareR , HeardA , ChanA . Substance abuse during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005;45(3):220-5. [DOI: 10.1111/j.1479-828X.2005.00379.x] [PMID: 15904448]">Kennare 2005</a>), reduce neuroanatomic volumes (<a href="./references#CD002059-bbs2-0160" title="WalhovdKB , MoeV , SlinningK , Due-TønnessenP , BjørnerudA , DaleAM , et al. Volumetric cerebral characteristics of children exposed to opiates and other substances in utero. Neuroimage2007;36(4):1331-44. [DOI: 10.1016/j.neuroimage.2007.03.070] [PMID: 17513131]">Walhovd 2007</a>), alter neuronal connective tracts on imaging studies (<a href="./references#CD002059-bbs2-0161" title="WalhovdKB , WattsR , AmlienI , WoodwardLJ . Neural tract development of infants born to methadone-maintained mothers. Pediatric Neurology2012;47(1):1-6. [DOI: 10.1016/j.pediatrneurol.2012.04.008] [PMID: 22704008]">Walhovd 2012</a>), reduce newborn head circumference (<a href="./references#CD002059-bbs2-0157" title="ViscontiK , HennessyK , TowersC , HannessyM , HowardB . Opiate use in pregnancy and newborn head circumference. American Journal of Obstetrics and Gynecology2013;208:S67-8.">Visconti 2013</a>), increase the risk of stillbirth (<a href="./references#CD002059-bbs2-0095" title="FinneganLP , KandallSR . Maternal and neonatal effects of alcohol and drugs. In: LowinsonJH , RuizP , MillmanRB , LangrodJG , editors(s). Substance Abuse: A Comprehensive Textbook. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2005:805-39.">Finnegan 2005</a>; <a href="./references#CD002059-bbs2-0114" title="KennareR , HeardA , ChanA . Substance abuse during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005;45(3):220-5. [DOI: 10.1111/j.1479-828X.2005.00379.x] [PMID: 15904448]">Kennare 2005</a>), neonatal mortality (<a href="./references#CD002059-bbs2-0104" title="HulseGK , MilneE , EnglishDR , HolmanCD . Assessing the relationship between maternal opiate use and neonatal mortality. Addiction1998;93(7):1033-42. [DOI: 10.1046/j.1360-0443.1998.93710338.x] [PMID: 9744134]">Hulse 1998</a>), and sudden infant death syndrome (<a href="./references#CD002059-bbs2-0112" title="KandallSR , GainesJ , HabelL , DavidsonG , JessopD . Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring. Journal of Pediatrics1993;123(1):120-6. [DOI: 10.1016/s0022-3476(05)81554-9] [PMID: 8320605]">Kandall 1993</a>). In the older child, failure to thrive and short stature (<a href="./references#CD002059-bbs2-0105" title="HuntRW , TzioumiD , CollinsE , JefferyHE . Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Human Development2008;84(1):29-35. [DOI: 10.1016/j.earlhumdev.2007.01.013] [PMID: 17728081]">Hunt 2008</a>), visual disturbances including refractive errors and nystagmus (<a href="./references#CD002059-bbs2-0147" title="Spiteri CornishK , HrabovskyM , ScottNW , MyerscoughE , ReddyAR . The short- and long-term effects on the visual system of children following exposure to maternal substance misuse in pregnancy. American Journal of Ophthalmology2013;156(1):190-4. [DOI: 10.1016/j.ajo.2013.02.004] [PMID: 23628351]">Spiteri Cornish 2013</a>), and psycho‐behavioural problems such as impulsivity and attention‐deficit that may in turn lead to failure at school (<a href="./references#CD002059-bbs2-0131" title="OeiJL , MelhuishE , UebelH , AzzamN , BreenC , BurnsL , et al. Neonatal abstinence syndrome and high school performance. Pediatrics2017;139(2):e20162651. [DOI: 10.1542/peds.2016-2651] [PMID: 28093465]">Oei 2017</a>; <a href="./references#CD002059-bbs2-0150" title="Sundelin WahlstenV , SarmanI . Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediatrics2013;102(5):544-9. [DOI: 10.1111/apa.12210] [PMID: 23432078]">Sundelin Wahlsten 2013</a>), have been associated with exposure in utero to opioids and other drugs. </p> </section> <section id="CD002059-sec-0011"> <h3 class="title" id="CD002059-sec-0011">Description of the intervention</h3> <p>Intervention begins with identification of infants with NAS. A variety of scoring systems identify and document the severity of clinical manifestations associated with NAS, including the Lipsitz tool (<a href="./references#CD002059-bbs2-0120" title="LipsitzPJ . A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clinical Pediatrics1975;14(6):592-4. [DOI: 10.1177/000992287501400613] [PMID: 1126108]">Lipsitz 1975</a>), Neonatal Abstinence Scoring System (<a href="./references#CD002059-bbs2-0029" title="FinneganLP , Connaughton JF Jr, KronRE , EmichJP . Neonatal abstinence syndrome: assessment and management. Addictive Diseases1975;2(1-2):141-58. [PMID: 1163358]">Finnegan 1975a</a>), Neonatal Narcotic Withdrawal Index (<a href="./references#CD002059-bbs2-0098" title="GreenM , SuffetF . The neonatal narcotic withdrawal index: a device for the improvement of care in the abstinence syndrome. American Journal of Drug and Alcohol Abuse1981;8(2):203-13. [DOI: 10.3109/00952998108999125] [PMID: 7331976]">Green 1981</a>), Neonatal Withdrawal Inventory (<a href="./references#CD002059-bbs2-0166" title="ZahorodnyW , RomC , WhitneyW , GiddensS , SamuelM , MaichukG , et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. Journal of Developmental and Behavioral Pediatrics1998;19(2):89-93. [DOI: 10.1097/00004703-199804000-00005] [PMID: 9584937]">Zahorodny 1998</a>), and the MOTHER NAS Scale (<a href="./references#CD002059-bbs2-0108" title="JonesHE , SeashoreC , JohnsonE , HortonE , O'GradyKE , AndringaK , et al. Psychometric assessment of the neonatal abstinence scoring system and the MOTHER NAS Scale. American Journal of Addiction2016;25(5):370-3. [DOI: 10.1111/ajad.12388] [PMID: 27287965]">Jones 2016</a>). There are internal consistency, reliability and validity concerns with the use of scoring systems for NAS (<a href="./references#CD002059-bbs2-0082" title="BagleySM , WachmanEM , HollandE , BroglySB . Review of the assessment and management of neonatal abstinence syndrome. Addiction Science &amp; Clinical Practice2014;9(1):19. [DOI: 10.1186/1940-0640-9-19] [ascpjournal.org/content/9/1/19] [PMID: 25199822]">Bagley 2014</a>; <a href="./references#CD002059-bbs2-0108" title="JonesHE , SeashoreC , JohnsonE , HortonE , O'GradyKE , AndringaK , et al. Psychometric assessment of the neonatal abstinence scoring system and the MOTHER NAS Scale. American Journal of Addiction2016;25(5):370-3. [DOI: 10.1111/ajad.12388] [PMID: 27287965]">Jones 2016</a>; <a href="./references#CD002059-bbs2-0164" title="WolffK , Perez-MontejanoR . Opioid neonatal abstinence syndrome: controversies and implications for practice. Current Drug Abuse Reviews2014;7(1):454-58. [DOI: 10.2174/1874473707666141015215141] [PMID: 25323126]">Wolff 2014</a>), many of which relate to clinician competency in identifying symptoms of NAS and using the tool effectively (<a href="./references#CD002059-bbs2-0133" title="OrlandoS . An overview of clinical tools used to assess neonatal abstinence syndrome. Journal of Perinatal &amp; Neonatal Nursing2014;28(3):212-9. [DOI: 10.1097/JPN.0000000000000043] [PMID: 25062523]">Orlando 2014</a>), particularly where preterm infants are concerned (<a href="./references#CD002059-bbs2-0081" title="AlloccoE , MelkerM , Rojas-MiquezF , BradleyC , HahnKA , WachmanEM . Comparison of neonatal abstinence syndrome manifestations in preterm versus term opioid-exposed infants. Advances in Neonatal Care2016;16(5):329-36. [DOI: 10.1097/ANC.0000000000000320] [PMID: 27611018]">Allocco 2016</a>). Despite these inadequacies, the Neonatal Abstinence Scoring System (<a href="./references#CD002059-bbs2-0029" title="FinneganLP , Connaughton JF Jr, KronRE , EmichJP . Neonatal abstinence syndrome: assessment and management. Addictive Diseases1975;2(1-2):141-58. [PMID: 1163358]">Finnegan 1975a</a>), or modified versions, remains the most commonly used method for assessing withdrawal symptoms and determining treatment (<a href="./references#CD002059-bbs2-0117" title="KraftWK , StoverNW , DavisJM . Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Seminars in Perinatology2016;40(3):203-12. [DOI: 10.1053/j.semperi.2015.12.007] [PMID: 26791055]">Kraft 2016</a>; <a href="./references#CD002059-bbs2-0069" title="NCT01671410. Buprenorphine for treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines (MOPPlus) [A randomized, open label clinical trial of buprenorphine in the treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines or are breastfeeding]. clinicaltrials.gov/ct2/show/NCT01671410 (first received 23 August 2012). ">NCT01671410</a>). In general, pharmacologic interventions are commenced once an infant scores more than 8 on the Neonatal Abstinence Scoring System (<a href="./references#CD002059-bbs2-0117" title="KraftWK , StoverNW , DavisJM . Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Seminars in Perinatology2016;40(3):203-12. [DOI: 10.1053/j.semperi.2015.12.007] [PMID: 26791055]">Kraft 2016</a>). More recently an 'eat, sleep, console' (ESC) assessment approach has been developed (<a href="./references#CD002059-bbs2-0099" title="GrossmanMR , LipshawMJ , OsbornRR , BerkwittAK . A novel approach to assessing infants with neonatal abstinence syndrome. Hospital Pediatrics2018;8:1-6. [DOI: 10.1542/hpeds.2017-0128]">Grossman 2018</a>). It identifies interruption in these functions which indicates that the infant is unable to perform activities of daily living and is having withdrawal symptoms that require pharmacological intervention (<a href="./references#CD002059-bbs2-0099" title="GrossmanMR , LipshawMJ , OsbornRR , BerkwittAK . A novel approach to assessing infants with neonatal abstinence syndrome. Hospital Pediatrics2018;8:1-6. [DOI: 10.1542/hpeds.2017-0128]">Grossman 2018</a>). </p> <p>The goal of treatment usually includes reducing a standardised score of NAS from a clinically significant level to a clinically 'safe' level (<a href="./references#CD002059-bbs2-0138" title="PatrickSW , BarfieldWD , PoindexterBB , AAP Committee on Fetus and Newborn, Committee on Substance Use and Prevention. Neonatal Opioid Withdrawal Syndrome. Pediatrics2020;146(5):e2020029074. [DOI: 10.1542/peds.2020-029074]">Patrick 2020</a>), according to the NAS scoring system used (<a href="./references#CD002059-bbs2-0029" title="FinneganLP , Connaughton JF Jr, KronRE , EmichJP . Neonatal abstinence syndrome: assessment and management. Addictive Diseases1975;2(1-2):141-58. [PMID: 1163358]">Finnegan 1975a</a>), or alternative assessment criteria such as the ESC approach (<a href="./references#CD002059-bbs2-0099" title="GrossmanMR , LipshawMJ , OsbornRR , BerkwittAK . A novel approach to assessing infants with neonatal abstinence syndrome. Hospital Pediatrics2018;8:1-6. [DOI: 10.1542/hpeds.2017-0128]">Grossman 2018</a>). </p> <p>Treatment for NAS typically involves a combination of pharmacologic and non‐pharmacologic interventions. Infants who fail treatment with a combination of a single pharmacological agent and non‐pharmacological agent may be treated with a second agent. Pharmacologic interventions for NAS due to opioid withdrawal have included tincture of opium, paregoric, morphine, methadone and, more recently, buprenorphine. Sedatives used for opioid withdrawal have included clonidine, phenobarbital, diazepam and chlorpromazine (<a href="./references#CD002059-bbs2-0069" title="NCT01671410. Buprenorphine for treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines (MOPPlus) [A randomized, open label clinical trial of buprenorphine in the treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines or are breastfeeding]. clinicaltrials.gov/ct2/show/NCT01671410 (first received 23 August 2012). ">NCT01671410</a>; <a href="./references#CD002059-bbs2-0146" title="SiuA , RobinsonCA . Neonatal abstinence syndrome: essentials for the practitioner. Journal of Pediatric Pharmacology and Therapeutics2014;19(3):147-55. [DOI: 10.5863/1551-6776-19.3.147] [PMID: 25309144]">Siu 2014</a>; <a href="./references#CD002059-bbs2-0151" title="TheisJG , SelbyP , IkizlerY , KorenGS . Current management of the neonatal abstinence syndrome: a critical analysis of the evidence. Biology of the Neonate1997;71(6):345-56. [DOI: 10.1159/000244435] [PMID: 9197336]">Theis 1997</a>). Non‐pharmacologic interventions have included reducing environmental stimuli, swaddling, settling, massage, relaxation baths, pacifiers and waterbeds (<a href="./references#CD002059-bbs2-0082" title="BagleySM , WachmanEM , HollandE , BroglySB . Review of the assessment and management of neonatal abstinence syndrome. Addiction Science &amp; Clinical Practice2014;9(1):19. [DOI: 10.1186/1940-0640-9-19] [ascpjournal.org/content/9/1/19] [PMID: 25199822]">Bagley 2014</a>; <a href="./references#CD002059-bbs2-0134" title="OroAS , DixonSD . Waterbed care of narcotic-exposed neonates. A useful adjunct to supportive care. American Journal of Diseases of Children1988;142(2):186-8. [DOI: 10.1001/archpedi.1988.02150020088036] [PMID: 3341322]">Oro 1988</a>). More recently, acupuncture (<a href="./references#CD002059-bbs2-0085" title="BoucherAM . Non-opioid management of neonatal abstinence syndrome. Advances in Neonatal Care2017;17(2):84-90. [DOI: 10.1097/ANC.0000000000000371] [PMID: 28002062]">Boucher 2017</a>; <a href="./references#CD002059-bbs2-0140" title="RaithW , SchmölzerBR , Fritz ReitererA . Laser acupuncture for neonatal abstinence syndrome: a randomised controlled trial. Pediatrics2015;136(5):876-84. [DOI: 10.1542/peds.2015-0676] [PMID: 26504123]">Raith 2015</a>), together with a much greater focus on promoting the mother‐infant dyad through rooming‐in programs (<a href="./references#CD002059-bbs2-0085" title="BoucherAM . Non-opioid management of neonatal abstinence syndrome. Advances in Neonatal Care2017;17(2):84-90. [DOI: 10.1097/ANC.0000000000000371] [PMID: 28002062]">Boucher 2017</a>; <a href="./references#CD002059-bbs2-0103" title="HowardMB , SchiffDM , PenwillN , RaiA , WolfgangT , MosesJM , et al. Impact of parental presence at infants' bedside on neonatal abstinence syndrome. Hospital Pediatrics2017;7(2):63-9. [DOI: 10.1542/hpeds.2016-0147] [PMID: 28137920]">Howard 2017</a>; <a href="./references#CD002059-bbs2-0129" title="NewmanA , DaviesGA , DowK , HolmesB , MacdonaldJ , McKinghtS , et al. Rooming-in care for infants of opioid-dependent mothers. Canadian Family Physician2015;61(12):e555-61. [PMID: 27035006]">Newman 2015</a>), and breastfeeding (<a href="./references#CD002059-bbs2-0106" title="JanssonLM , SpencerN , McConnellK , VelezM , TutenM , HarrowCA , et al. Maternal buprenorphine maintenance and lactation. Journal of Human Lactation2016;32(4):675-81. [DOI: 10.1177/0890334416663198] [PMID: 27563013]">Jansson 2016</a>; <a href="./references#CD002059-bbs2-0145" title="ShortVL , GannonM , AbatemarcoDJ . The association between breastfeeding and length of hospital stay among infants diagnosed with neonatal abstinence syndrome: a population-based study on in-hospital births. Breastfeeding Medicine : the Official Journal of the Academy of Breastfeeding Medicine2016;11:343-9. [DOI: 10.1089/bfm.2016.0084] [PMID: 27529500]">Short 2016</a>), have been shown to reduce the need for pharmacologic intervention, decrease the severity of NAS symptoms and reduce hospital length of stay (LOS). However, as two recent reviews have shown, there are no high‐quality clinical trials supporting efficacy of non‐pharmacologic treatment interventions (<a href="./references#CD002059-bbs2-0122" title="MacMillanKD , RendonCP , VermaK , RibletN , WasherDB , HolmesAV . Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatrics2018;172(4):345-51. [DOI: 10.1001/jamapediatrics.2017.5195] [PMID: 29404599]">MacMillan 2018</a>; <a href="./references#CD002059-bbs2-0159" title="WachmanEM , SchiffDM , SilversteinM . Neonatal abstinence syndrome: advances in diagnosis and treatment. JAMA2018;319(13):1362-74. [DOI: 10.1001/jama.2018.2640] [PMID: 29614184]">Wachman 2018</a>). There are also no current randomised clinical trials of the ESC approach. </p> </section> <section id="CD002059-sec-0012"> <h3 class="title" id="CD002059-sec-0012">How the intervention might work</h3> <p>Following delivery, the abrupt cessation of opioid supply to the newborn results in a cascade of neurotransmitter activity, which involves an increase in the production of noradrenaline, acetylcholine and corticotrophin, as well as a decrease in the production of serotonin and dopamine (<a href="./references#CD002059-bbs2-0116" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-e61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>). Pharmacologic interventions for NAS due to opioid withdrawal include opioid replacement therapies directed towards the μ‐opioid receptor. These include tincture of opium (contains ethanol 19%, and opium alkaloids including morphine and codeine), paregoric (contains ethanol 44%, anhydrous morphine, camphor, anise oil, benzoic acid, glycerine and antispasmodics ‐ papaverine and noscapine), morphine (natural opioid), methadone (a synthetic μ‐opioid receptor agonist) and, more recently, buprenorphine (a semi‐synthetic partial μ‐opioid receptor agonist and complete κ‐opioid receptor antagonist). Sedatives used for opioid withdrawal have included clonidine (an α2 adrenergic receptor agonist), phenobarbital and diazepam, gamma‐aminobutyric acid (GABA) (receptor agonists that bind to different sites on the receptor) and chlorpromazine (a dopamine antagonist) (<a href="./references#CD002059-bbs2-0069" title="NCT01671410. Buprenorphine for treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines (MOPPlus) [A randomized, open label clinical trial of buprenorphine in the treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines or are breastfeeding]. clinicaltrials.gov/ct2/show/NCT01671410 (first received 23 August 2012). ">NCT01671410</a>; <a href="./references#CD002059-bbs2-0146" title="SiuA , RobinsonCA . Neonatal abstinence syndrome: essentials for the practitioner. Journal of Pediatric Pharmacology and Therapeutics2014;19(3):147-55. [DOI: 10.5863/1551-6776-19.3.147] [PMID: 25309144]">Siu 2014</a>; <a href="./references#CD002059-bbs2-0151" title="TheisJG , SelbyP , IkizlerY , KorenGS . Current management of the neonatal abstinence syndrome: a critical analysis of the evidence. Biology of the Neonate1997;71(6):345-56. [DOI: 10.1159/000244435] [PMID: 9197336]">Theis 1997</a>). </p> <p>The goals of therapy are to ensure that the infant achieves adequate sleep and nutrition to establish a consistent pattern of weight gain, and begins to integrate into a social environment. The goal of pharmacologic treatment is achievement of the desired therapeutic effect by using the smallest amount of drugs at the lowest doses and for the shortest durations possible (<a href="./references#CD002059-bbs2-0078" title="HudakML , TanRC , Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics2012;129(2):e540-60. [DOI: 10.1542/peds.2011-3212] [PMID: 22291123]">AAP 2012</a>). Treatment is usually initiated and titrated to NAS withdrawal scores. Once stabilised, treatment is withdrawn whilst continuing to monitor NAS withdrawal scores. In infants with predominant opioid dependency, opioid replacement therapy is usually titrated down gradually, whereas sedatives prescribed for relatively short periods can be titrated more rapidly, allowing for shorter durations of treatment and earlier discharge of infants from hospital. However, although it is common for infants on pharmacological treatment for NAS to remain in hospital, there are increasing reports of safe discharge of infants on treatment (<a href="./references#CD002059-bbs2-0113" title="KellyLE , KnoppertD , RoukemaH , RiederMJ , KorenG . Oral morphine weaning for neonatal abstinence syndrome at home compared with in-hospital: an observational cohort study. Paediatric Drugs2015;17(2):151-7. [DOI: 10.1007/s40272-014-0096-y] [PMID: 25342143]">Kelly 2015</a>; <a href="./references#CD002059-bbs2-0127" title="MiddletonM , WrightI , OeiJL , TravadiJ . Management of infants with neonatal abstinence syndrome in a tertiary care hospital. Journal of Paediatrics and Child Health2017;53(Supplement 2):106.">Middleton 2017</a>). </p> <p>Multiple excipients and other opioids are present in many compounds and may have clinical effects. It remains unclear what ethanol exposure is safe for neonates and infants. The United States' Food and Drug Administration (FDA) has set a maximum limit of 0.5% ethanol in oral over‐the‐counter products intended for children younger than six years old, and the American Academy of Pediatrics' Committee on Drugs and the European Medicines Agency have also set limits (<a href="./references#CD002059-bbs2-0124" title="MarekE , KraftWK . Ethanol pharmacokinetics in neonates and infants. Current Therapeutic Research, Clinical and Experimental2014;76:90-7. [DOI: 10.1016/j.curtheres.2014.09.002] [PMID: 25379066]">Marek 2014</a>). </p> </section> <section id="CD002059-sec-0013"> <h3 class="title" id="CD002059-sec-0013">Why it is important to do this review</h3> <p>Recommended first line pharmacologic treatment for newborns experiencing NAS from opioid withdrawal is generally with an opioid and may include adjunctive treatment with a sedative (<a href="./references#CD002059-bbs2-0078" title="HudakML , TanRC , Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics2012;129(2):e540-60. [DOI: 10.1542/peds.2011-3212] [PMID: 22291123]">AAP 2012</a>). Non‐pharmacologic treatments directed at rooming‐in, skin‐to‐skin contact and breastfeeding are also advantageous (<a href="./references#CD002059-bbs2-0122" title="MacMillanKD , RendonCP , VermaK , RibletN , WasherDB , HolmesAV . Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatrics2018;172(4):345-51. [DOI: 10.1001/jamapediatrics.2017.5195] [PMID: 29404599]">MacMillan 2018</a>; <a href="./references#CD002059-bbs2-0159" title="WachmanEM , SchiffDM , SilversteinM . Neonatal abstinence syndrome: advances in diagnosis and treatment. JAMA2018;319(13):1362-74. [DOI: 10.1001/jama.2018.2640] [PMID: 29614184]">Wachman 2018</a>), but may be challenging for clinicians to facilitate. The question addressed by this review is: what is the evidence, from randomised and quasi‐randomised controlled trials, that an opioid is better than a sedative or non‐pharmacological treatment of clinically significant NAS due to opioid withdrawal? The goal of treatment should be to provide comfort to the mother and infant in relieving symptoms, improve feeding and weight gain, prevent seizures, reduce unnecessary hospitalisation, improve mother‐infant interaction and reduce the incidence of infant mortality and abnormal neurodevelopment. This is an update of a previous review (<a href="./references#CD002059-bbs2-0169" title="OsbornDA , ColeMJ , JefferyHE . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD002059. [DOI: 10.1002/14651858.CD002059]">Osborn 2002</a>; <a href="./references#CD002059-bbs2-0170" title="OsbornDA , JefferyHE , ColeMJ . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002059. [DOI: 10.1002/14651858.CD002059.pub2]">Osborn 2005</a>; <a href="./references#CD002059-bbs2-0171" title="OsbornDA , JefferyHE , ColeM . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD002059. [DOI: 10.1002/14651858.CD002059.pub3]">Osborn 2010</a>). Separate reviews examine the evidence for the use of sedatives in infants with NAS due to opioid withdrawal (<a href="./references#CD002059-bbs2-0167" title="ZanklA , MartinJ , DaveyJG , OsbornDA . Sedatives for opioid withdrawal in newborn infants. Cochrane Database of Systematic Reviews2021;(in press).">Zankl 2021</a>), and non‐pharmacological care for opioid withdrawal in newborns (<a href="./references#CD002059-bbs2-0135" title="PahlA , YoungL , Buus‐FrankME , MarcellusL , SollR . Non‐pharmacological care for opioid withdrawal in newborns. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD013217. [DOI: 10.1002/14651858.CD013217.pub2]">Pahl 2020</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002059-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002059-sec-0014"></div> <p>To assess the effectiveness and safety of using an opioid for treatment of NAS due to withdrawal from opioids in newborn infants. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002059-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002059-sec-0015"></div> <section id="CD002059-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002059-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered all published and unpublished trials using random or quasi‐random participant allocation. Cluster‐randomised trials, where the unit of randomisation is a group of participants, were eligible for inclusion. Cross‐over trials were not eligible. </p> </section> <section id="CD002059-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included infants with NAS in the neonatal period born to mothers with an opioid dependence. Withdrawal needed to have been determined by the presence of symptoms consistent with NAS or the use of a standardised score of NAS. </p> </section> <section id="CD002059-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Trials comparing the following interventions were eligible for inclusion.</p> <p><b>Comparison 1: opioid versus placebo or no treatment / usual care ‐ specific comparisons:</b> </p> <p> <ul class="plain" id="CD002059-list-0001"> <li> <ol id="CD002059-list-0002"> <li> <p>morphine versus placebo or no treatment / usual care;</p> </li> <li> <p>diluted tincture of opium versus placebo or no treatment / usual care;</p> </li> <li> <p>paregoric versus placebo or no treatment / usual care;</p> </li> <li> <p>methadone versus placebo or no treatment / usual care; or</p> </li> <li> <p>buprenorphine versus placebo or no treatment / usual care.</p> </li> </ol> </li> </ul> </p> <p><b>Comparison 2: opioid versus another opioid ‐ specific comparisons:</b> </p> <p> <ul class="plain" id="CD002059-list-0003"> <li> <ol id="CD002059-list-0004"> <li> <p>morphine versus methadone;</p> </li> <li> <p>morphine versus paregoric;</p> </li> <li> <p>morphine versus buprenorphine;</p> </li> <li> <p>diluted tincture of opium versus paregoric;</p> </li> <li> <p>diluted tincture of opium versus morphine;</p> </li> <li> <p>diluted tincture of opium versus methadone;</p> </li> <li> <p>diluted tincture of opium versus buprenorphine;</p> </li> <li> <p>methadone versus paregoric; or</p> </li> <li> <p>methadone versus buprenorphine.</p> </li> </ol> </li> </ul> </p> <p><b>Comparison 3: opioid versus sedative ‐ specific comparisons:</b> </p> <p> <ul class="plain" id="CD002059-list-0005"> <li> <ol id="CD002059-list-0006"> <li> <p>morphine versus clonidine;</p> </li> <li> <p>morphine versus benzodiazepine;</p> </li> <li> <p>morphine versus phenobarbital;</p> </li> <li> <p>morphine versus clonazepam;</p> </li> <li> <p>diluted tincture of opium versus clonidine;</p> </li> <li> <p>diluted tincture of opium versus benzodiazepine;</p> </li> <li> <p>diluted tincture of opium versus phenobarbital;</p> </li> <li> <p>diluted tincture of opium versus clonazepam;</p> </li> <li> <p>paregoric versus clonidine;</p> </li> <li> <p>paregoric versus benzodiazepine;</p> </li> <li> <p>paregoric versus phenobarbital;</p> </li> <li> <p>paregoric versus clonazepam;</p> </li> <li> <p>methadone versus clonidine;</p> </li> <li> <p>methadone versus benzodiazepine;</p> </li> <li> <p>methadone versus phenobarbital;</p> </li> <li> <p>methadone versus clonazepam</p> </li> <li> <p>buprenorphine versus benzodiazepine;</p> </li> <li> <p>buprenorphine versus phenobarbital;</p> </li> <li> <p>buprenorphine versus clonazepam; or</p> </li> <li> <p>buprenorphine versus clonidine.</p> </li> </ol> </li> </ul> </p> <p><b>Comparison 4: addition of an opioid versus placebo or no treatment in sedative‐treated infants:</b> </p> <p> <ul class="plain" id="CD002059-list-0007"> <li> <ol id="CD002059-list-0008"> <li> <p>Including any of the comparisons documented above in comparisons 1 to 3.</p> </li> </ol> </li> </ul> </p> </section> <section id="CD002059-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes are reported to discharge or latest time measured, as appropriate.</p> <section id="CD002059-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002059-list-0009"> <li> <p>Treatment failure: including failure to achieve control, defined as a failure to reduce a standardised score of NAS from a clinically significant level to a clinically 'safe' level defined by author of trial, or the use of additional pharmacological treatments for control of NAS in the neonatal period. </p> </li> <li> <p>Seizures (paroxysmal alterations in neurological function. This can be behavioural, motor or autonomic (<a href="./references#CD002059-bbs2-0158" title="VolpeJJ . Neonatal seizures. In: VolpeJ , editors(s). Neurology of the Newborn. Philadelphia (PA): Saunders Elsevier, 2008:203-44. [ISBN: 9781416039952]">Volpe 2008</a>). Neonatal seizures can be clinical (with no EEG correlate), electroclinical (clinical associated with EEG findings) or electrographic (no clinical correlate) (<a href="./references#CD002059-bbs2-0128" title="MizrahiEM , KellawayP . Characterization and classification of neonatal seizures. Neurology1987;37(12):1837-44. [DOI: 10.1212/wnl.37.12.1837] [PMID: 3683874]">Mizrahi 1987</a>).) </p> </li> <li> <p>Neonatal (latest time reported to discharge) and infant mortality.</p> </li> <li> <p>Neurodevelopmental disability at 18 months' postnatal age or greater, defined as a neurological abnormality including any one of the following. </p> <ol id="CD002059-list-0010"> <li> <p>Cerebral palsy on clinical examination.</p> </li> <li> <p>Developmental delay more than two standard deviation (SDs) below population mean on a standardised test of development. </p> </li> <li> <p>Blindness (visual acuity less than 6/60).</p> </li> <li> <p>Deafness (any hearing impairment requiring amplification) at any time after term corrected.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD002059-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD002059-list-0011"> <li> <p>Time to control of NAS (control of symptoms or reduction of NAS score to a clinically 'safe' level). </p> </li> <li> <p>Days admission to a newborn nursery.</p> </li> <li> <p>Days hospitalisation.</p> </li> <li> <p>Days pharmacological treatment of NAS.</p> </li> <li> <p>Days to establishment of full sucking feeds.</p> </li> <li> <p>Success of breastfeeding (exclusive breastfeeding; partial breastfeeding ‐ at discharge; one, four and six months). </p> </li> <li> <p>Postnatal growth failure (weight &lt; 10th percentile at discharge)</p> </li> <li> <p>Infant growth: up to age one month; at latest time measured (definition = from one month to time of discharge); to follow‐up beyond 12 months: </p> <ol id="CD002059-list-0012"> <li> <p>weight gain (g/kg per day);</p> </li> <li> <p>linear growth (cm/week);</p> </li> <li> <p>head circumference (cm/week).</p> </li> </ol> </li> <li> <p>Change of standardised growth: up to age one month; at latest time measured (definition = from one month to time of discharge); to follow‐up beyond 12 months: </p> <ol id="CD002059-list-0013"> <li> <p>change in weight z‐score;</p> </li> <li> <p>change in length z‐score;</p> </li> <li> <p>change in head circumference z‐score.</p> </li> </ol> </li> <li> <p>Side effects occurring after commencement of therapy:</p> <ol id="CD002059-list-0014"> <li> <p>apnoea;</p> </li> <li> <p>need for resuscitation;</p> </li> <li> <p>need for mechanical ventilation.</p> </li> </ol> </li> <li> <p>Disruption to the mother‐infant relationship (e.g. separation of mother and infant, admission to a newborn nursery, failure to successfully breastfeed, maternal depression, or parental dissatisfaction). </p> </li> <li> <p>Out of home care (foster care; adoption).</p> </li> </ol> </p> </section> </section> </section> <section id="CD002059-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002059-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive updated search in September 2020 including: Cochrane Central Register of Controlled Trials (CENTRAL 2020, Issue 9) in the Cochrane Library; Ovid MEDLINE and Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Daily and Versions (2010 to 17 September 2020). We have included the search strategies for each database in <a href="./appendices#CD002059-sec-0132">Appendix 1</a>. We did not apply language restrictions. </p> <p>We searched clinical trial registries for ongoing or recently completed trials. We searched the World Health Organization's International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>), and the US National Library of Medicine’s ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>), via Cochrane CENTRAL. Additionally, we searched the ISRCTN Registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>), for any unique trials not found through the Cochrane CENTRAL search. </p> <p>We used Cochrane’s Screen4Me workflow to help assess the search results. Screen4Me comprises three components: known assessments – a service that matches records in the search results to records that have already been screened in Cochrane Crowd and been labelled as an <i>RCT</i> or as <i>Not an RCT</i>; and the RCT classifier – a machine learning model that distinguishes RCTs from non‐RCTs. </p> <p>For more information about Screen4Me and the evaluations that have been done, please go to the Screen4Me webpage on the Cochrane Information Specialist’s portal (<a href="http://community.cochrane.org/organizational-info/resources/resources-groups/information-specialists-portal/crs-videos-and-quick-reference-guides#Screen4Me" target="_blank">community.cochrane.org/organizational-info/resources/resources-groups/information-specialists-portal/crs-videos-and-quick-reference-guides#Screen4Me</a>). In addition, more detailed information regarding evaluations of the Screen4Me components can be found in the following publications: <a href="./references#CD002059-bbs2-0125" title="MarshallIJ , Noel-StorrAH , KuiperJ , ThomasJ , WallaceBC . Machine learning for identifying randomized controlled trials: an evaluation and practitioner’s guide. Research Synthesis Methods2018;9(4):602-14. [DOI: 10.1002/jrsm.1287] [PMID: 29314757]">Marshall 2018</a>; <a href="./references#CD002059-bbs2-0126" title="McDonaldS , Noel-StorrAH , ThomasJ . Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. In: abstracts.cochrane.org/2017-global-evidence-summit/harnessing-efficiencies-machine-learning-and-cochrane-crowd-identify. Cape Town, South Africa: Global Evidence Summit, 13 to 16 September 2017.">McDonald 2017</a>; <a href="./references#CD002059-bbs2-0130" title="Noel-StorrAH , Project Transform team. Cochrane Crowd: new ways of working together to produce health evidence. In: abstracts.cochrane.org/2019-santiago/cochrane-crowd-and-classmate-new-ways-working-and-learning-together-produce-health. Oxford, UK: Evidence Live 2018, 18 to 20 June 2018.">Noel‐Storr 2018</a>; <a href="./references#CD002059-bbs2-0152" title="ThomasJ , Noel-StorrAH , MarshallI , WallaceB , McDonaldS , MavergamesC , et al, Living Systematic Review Network. Living systematic reviews: 2. Combining human and machine effort. Journal of Clinical Epidemiology2017;91:31-7. [DOI: 10.1016/j.jclinepi.2017.08.011] [PMID: 28912003]">Thomas 2017</a>. </p> <p>This is the third update of this review. Previous search details are listed in <a href="./appendices#CD002059-sec-0136">Appendix 2</a>. </p> </section> <section id="CD002059-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also included in our search strategy searches of citations of included studies for references to other trials; previous reviews including cross‐references; abstracts and conference and symposia proceedings of Pediatric Academic Societies (American Pediatric Society, Society for Pediatric Research and European Society of Paediatric Research to 2019) and the Perinatal Society of Australia and New Zealand from 2010 to 2019. We contacted the corresponding investigator for information if we identified any unpublished trials. We considered unpublished studies or studies only reported as abstracts as eligible for inclusion in the review if methods and data could be confirmed by the author. </p> </section> </section> <section id="CD002059-sec-0026"> <h3 class="title" id="CD002059-sec-0026">Data collection and analysis</h3> <p>We used the standard methods of Cochrane as documented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002059-bbs2-0102" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>), and recommended by Cochrane Neonatal. </p> <section id="CD002059-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We (AZ, JM, DO) independently assessed for inclusion all the potential studies identified as a result of the search strategy. We resolved any differences of opinion through discussion. </p> </section> <section id="CD002059-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For the 2021 review update, we included additional studies as mentioned above. Three review authors (AZ, JM, DO) independently extracted data using a specifically designed data extraction sheet to manage information. We resolved any differences in opinion through discussion. We entered data into Review Manager software (<a href="./references#CD002059-bbs2-0141" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>), and cross‐checked for accuracy. One review author (DO) extracted data and requested additional data from the authors of three trials (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>), for the 2010 review update (<a href="./references#CD002059-bbs2-0171" title="OsbornDA , JefferyHE , ColeM . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD002059. [DOI: 10.1002/14651858.CD002059.pub3]">Osborn 2010</a>), which remains current for this review. DO and HJ extracted data independently then compared data and resolved differences for the 2005 update (<a href="./references#CD002059-bbs2-0170" title="OsbornDA , JefferyHE , ColeMJ . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002059. [DOI: 10.1002/14651858.CD002059.pub2]">Osborn 2005</a>), and 2002 review (<a href="./references#CD002059-bbs2-0169" title="OsbornDA , ColeMJ , JefferyHE . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD002059. [DOI: 10.1002/14651858.CD002059]">Osborn 2002</a>). </p> </section> <section id="CD002059-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (AZ, JM, DO) independently assessed the risk of bias (low, high, or unclear) of all included trials using the Cochrane risk of bias tool (<a href="./references#CD002059-bbs2-0101" title="HigginsJP , AltmanDG , SterneJA , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), for these domains: </p> <p> <ol id="CD002059-list-0015"> <li> <p>sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias);</p> </li> <li> <p>any other bias.</p> </li> </ol> </p> <p>We resolved any disagreements through discussion or by involving a third assessor. See <a href="./appendices#CD002059-sec-0137">Appendix 3</a> for a more detailed description of risk of bias for each domain. </p> </section> <section id="CD002059-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We carried out statistical analysis using the statistical package in Review Manager 5 (<a href="./references#CD002059-bbs2-0141" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We summarised the data in a meta‐analysis if they were sufficiently homogeneous, both clinically and statistically. </p> <section id="CD002059-sec-0031"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we present results using risk ratios (RR) and risk differences (RD) with 95% confidence intervals (CIs). We calculated the number needed to treat to for an additional beneficial outcome (NNTB), or the number needed to treat for an additional harmful outcome (NNTH) with 95% CIs if there was a statistically significant reduction (or increase) in RD. </p> </section> <section id="CD002059-sec-0032"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference (MD) when outcomes were measured in the same way between trials. We used the standardised mean difference (SMD) to combine trials that measured the same outcome but used different methods. Where trials reported continuous data as median and interquartile range (IQR) and data passed the test of skewness, we converted mean to median and estimated the standard deviation as IQR/1.35. </p> </section> </section> <section id="CD002059-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the intended unit of analysis. Cluster‐randomised controlled trials were eligible. </p> <section id="CD002059-sec-0034"> <h5 class="title">Cluster‐randomised trials</h5> <p>We intended to analyse cluster‐randomised trials in the analyses along with individually randomised trials. We intended to analyse them using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002059-bbs2-0102" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>), using an estimate of the intra‐cluster correlation coefficient (ICC) derived from the trial (if possible) or from another source. If ICCs from other sources were used, we reported this, and conducted a sensitivity analysis to investigate the effect of variations in the ICC. Where we identified cluster‐randomised trials and individually randomised trials, we synthesised relevant information. We considered it reasonable to combine the results from both if there was little heterogeneity between study designs, and if interaction between effect of the intervention and choice of randomisation unit was unlikely. </p> </section> </section> <section id="CD002059-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We obtained missing data from the authors when possible. Where missing data could not be obtained, we planned to examine the effect of excluding trials with substantial missing data (e.g. greater than 10% losses) in sensitivity analyses. </p> <p>We planned to attempt to overcome potential bias from missing data (greater than 10% losses) using one or more of the following approaches. </p> <p> <ol id="CD002059-list-0016"> <li> <p>Whenever possible, contacting the original investigators to request missing data.</p> </li> <li> <p>Performing sensitivity analyses to assess how sensitive the results are to reasonable changes in the assumptions made (e.g. the effect of excluding trials with substantial missing data (greater than 10% losses)). </p> </li> <li> <p>Addressing the potential impact of missing data (greater than 10% losses) upon the findings of the review in the discussion section. </p> </li> </ol> </p> </section> <section id="CD002059-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used Review Manager 5 to assess the heterogeneity of treatment effects between trials (<a href="./references#CD002059-bbs2-0141" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>), using the two statistical methods described below. </p> <p> <ol id="CD002059-list-0017"> <li> <p>The Chi<sup>2</sup> test, to assess whether observed variability in effect sizes between studies is greater than would be expected by chance. Since this test has low power when the number of studies included in the meta‐analysis is small, we plan to set the probability at the 10% level of significance. </p> </li> <li> <p>The I<sup>2</sup> statistic to ensure that pooling of data is valid. We considered a degree of heterogeneity less than 25% to represent no heterogeneity, 25% to 49% to represent minimal heterogeneity, 50% to 74% to represent moderate heterogeneity, and 75% or greater representing substantial or high heterogeneity. </p> </li> </ol> </p> <p>We assessed the source of heterogeneity using sensitivity and subgroup analysis, looking for evidence of bias or methodological differences between trials where there was evidence of apparent or statistical heterogeneity. </p> </section> <section id="CD002059-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias by comparing the stated primary and secondary outcomes and the reported outcomes. Where study protocols were available, we compared these to the full publications to determine the likelihood of reporting bias. We documented studies using the interventions in a potentially eligible infant population but not reporting on any of the primary and secondary outcomes in the <a href="./references#CD002059-sec-0154" title="">Characteristics of included studies</a> tables. We used funnel plots to screen for publication bias where there were a sufficient number of studies (&gt; 10) reporting the same outcome. If publication bias was suggested by a significant asymmetry of the funnel plot on visual assessment, we planned to incorporate this in our assessment of the certainty of evidence </p> </section> <section id="CD002059-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 (<a href="./references#CD002059-bbs2-0141" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We used the fixed‐effect model inverse variance meta‐analysis for combining data where trials examined the same intervention and the populations and methods of the trials were judged to be similar. We intended to assess possible source(s) of heterogeneity using subgroup and sensitivity analysis. </p> </section> <section id="CD002059-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Prespecified subgroup analyses included the following subcategories.</p> <p> <ol id="CD002059-list-0018"> <li> <p>According to dosage of opioid used: subgroup analysis was performed for treatment failure using morphine maximal dose of 0.5 mg/kg/day or higher versus less than 0.5 mg/kg/day as a post hoc defined cut‐off point. </p> </li> <li> <p>According to route of administration.</p> </li> <li> <p>According to whether trials included mothers with only opioid dependence or with polydrug use. </p> </li> <li> <p>According to age at treatment (e.g. early versus delayed treatment) and duration of treatment (e.g. short versus long course). </p> </li> </ol> </p> <p>We included all outcomes where available in subgroup analysis.</p> <p>We explored heterogeneity through subgroup analysis as above, and sensitivity analysis according to study quality. </p> </section> <section id="CD002059-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analyses on the basis of methodological quality. We defined studies with sound methodology as those with adequate randomisation and allocation concealment measures, blinding of treatment and greater than 90% follow‐up on an intention‐to‐treat basis. </p> </section> <section id="CD002059-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE Handbook</a> (<a href="./references#CD002059-bbs2-0144" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>), to assess the certainty of evidence for these (clinically relevant) outcomes: </p> <p> <ol id="CD002059-list-0019"> <li> <p>treatment failure;</p> </li> <li> <p>seizures;</p> </li> <li> <p>neonatal or infant mortality;</p> </li> <li> <p>neurodevelopmental disability;</p> </li> <li> <p>duration of hospitalisation (days);</p> </li> <li> <p>duration of treatment (days);</p> </li> <li> <p>adverse events.</p> </li> </ol> </p> <p>Two review authors (AZ, DO) independently assessed the certainty of the evidence for each of the outcomes above. We considered evidence from RCTs as high certainty but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used the <a href="./references#CD002059-bbs2-0097" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 24 April 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2017. Available at gradepro.org.">GRADEpro GDT</a> Guideline Development Tool to create eight summary of findings tables to report the certainty of the evidence. </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence in one of four grades: </p> <p> <ol id="CD002059-list-0020"> <li> <p>high certainty: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>very low certainty: we are very uncertain about the estimate.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002059-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002059-sec-0042"></div> <section id="CD002059-sec-0043"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD002059-sec-0154" title="">Characteristics of included studies</a> table. </p> <section id="CD002059-sec-0044"> <h4 class="title">Results of the search</h4> <p>The search was updated in September 2020 (<a href="#CD002059-fig-0001">Figure 1</a>; <a href="#CD002059-fig-0002">Figure 2</a>). In total, we excluded 52 studies (55 reports) (see <a href="./references#CD002059-sec-0155" title="">Characteristics of excluded studies</a>). Sixteen studies (29 reports) were eligible for inclusion (see <a href="./references#CD002059-sec-0154" title="">Characteristics of included studies</a>). Four studies are awaiting classification as they are recorded as being completed but are yet to publish results (see <a href="./references#CD002059-sec-0156" title="">Characteristics of studies awaiting classification</a>). These include three studies of buprenorphine versus morphine (<a href="./references#CD002059-bbs2-0068" title="IRCT20181231042183N1. Assessment effect of bopronorphin neonates with obstinence syndrom [Comparison bopronorphin and morphin among neonates with obstinence syndrom admitted In Birjand Vali-asr Hospital]. en.irct.ir/trial/36431 (first received 18 January 2019). ">IRCT20181231042183N1</a>; <a href="./references#CD002059-bbs2-0069" title="NCT01671410. Buprenorphine for treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines (MOPPlus) [A randomized, open label clinical trial of buprenorphine in the treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines or are breastfeeding]. clinicaltrials.gov/ct2/show/NCT01671410 (first received 23 August 2012). ">NCT01671410</a>; <a href="./references#CD002059-bbs2-0070" title="NCT01708707. A randomized comparison of sublingual buprenorphine to morphine sulfate in the treatment of neonatal abstinence syndrome (NAS) [Comparison of buprenorphine to morphine in treatment of neonatal abstinence syndrome (NAS)]. clinicaltrials.gov/ct2/show/nct01708707 (first received 17 October 2012). ">NCT01708707</a>), and a study comparing phenobarbital and methadone versus phenobarbital and dilute tincture of opium (DTO) (<a href="./references#CD002059-bbs2-0071" title="NCT01723722. Treatment of Neonatal Abstinence Syndrome (HOMENOW) [Treatment of neonatal abstinence syndrome: evaluation of efficacy of phenobarbital in combination with either methadone or diluted deodorized tincture of opium as stabilizing and tapering regiments]. clinicaltrials.gov/ct2/show/NCT01723722 (first received 8 November 2012). ">NCT01723722</a>). Six studies are ongoing (see <a href="./references#CD002059-sec-0157" title="">Characteristics of ongoing studies</a>). These include studies of morphine versus methadone (<a href="./references#CD002059-bbs2-0072" title="NCT02851303. Morphine versus methadone for opiate exposed infants with neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT02851303 (first received 1 August 2016). ">NCT02851303</a>, <a href="./references#CD002059-bbs2-0077" title="NCT04455802. Randomized control trial of buprenorphine vs. morphine for the treatment of neonatal opioid withdrawal syndrome (NOWS) [Prospective randomized blinded trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS)]. clinicaltrials.gov/ct2/show/NCT04455802 (first received 2 July 2020). ">NCT04455802</a>), clonidine versus morphine (<a href="./references#CD002059-bbs2-0073" title="NCT03092011. Treatment of neonatal abstinence syndrome with clonidine versus morphine as primary therapy. clinicaltrials.gov/show/NCT03092011 (first received 27 March 2017). ">NCT03092011</a>), buprenorphine versus morphine (<a href="./references#CD002059-bbs2-0074" title="NCT04104646. CHF6563 in babies with neonatal opioid withdrawal syndrome [A phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with neonatal opioid withdrawal syndrome]. clinicaltrials.gov/ct2/show/NCT04104646 (first received 26 September 2019). ">NCT04104646</a>), rapid versus slow wean of dose of morphine or methadone (<a href="./references#CD002059-bbs2-0075" title="NCT04214834. Trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS) [Pragmatic, randomized, blinded trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS)]. clinicaltrials.gov/ct2/show/NCT04214834 (first received 2 January 2020). ">NCT04214834</a>), morphine titrated according to protocol versus morphine as needed (<a href="./references#CD002059-bbs2-0076" title="NCT04298853. Optimal morphine dosing schedule for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT04298853 (first received 6 March 2020). ">NCT04298853</a>). </p> <div class="figure" id="CD002059-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update 2020" data-id="CD002059-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update 2020</p> </div> </div> </div> <div class="figure" id="CD002059-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Screen4Me summary diagram" data-id="CD002059-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Screen4Me summary diagram</p> </div> </div> </div> </section> <section id="CD002059-sec-0045"> <h4 class="title">Included studies</h4> <p>We assessed 16 studies as eligible for inclusion (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). Two studies (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>), may be sequential reports in which some of the infants are the same (author communication: <a href="./references#CD002059-bbs2-0109" title="KaltenbachK . Personal communication. Conversation with K Kaltenbach March 2004.">Kaltenbach 2004</a>). We used data from <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> for outcomes common to both reports to avoid double reporting. </p> <section id="CD002059-sec-0046"> <h5 class="title">Participants</h5> <p>Eleven of the 16 included studies have taken place in the USA. Australia, Germany, Iran, Scotland and Switzerland contributed one study each. A total of 1110 infants participated in the studies. Three studies enrolled infants born to mothers using only opioids (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). One study reported infants born to mothers using only opioids separately from infants born to mothers using opioids and other drugs (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>). Twelve studies included infants both born to mothers using only opioids, and those born to mothers using opioids and other drugs (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). No study reported including infants with NAS secondary to medically prescribed opioids used in the nursery. The infants were predominately of term or near term gestational age. </p> <p>The majority of studies used a validated NAS scoring system to determine eligibility for treatment. Two studies used the Lipsitz score (<a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>), and commenced treatment with two sequential scores above 4 or a single score of 7 or more. Thirteen studies used the Finnegan score or a modification thereof, with treatment usually commenced when the average of three consecutive scores was 8 or more, or a single score was 12 or more (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). One study used the MOTHER NAS scale with threshold for pharmacologic treatment the sum of three scores of 24 or more or a single score of 12 or more (<a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). A single study did not use a formal NAS scoring system but used clinical decision to treat (<a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). </p> <p>See <a href="./references#CD002059-sec-0154" title="">Characteristics of included studies</a> for details of each study criteria and titration. </p> </section> <section id="CD002059-sec-0047"> <h5 class="title">Interventions</h5> <p>Fourteen of the 16 studies titrated the dosage of treatment according to the NAS scoring system (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). A single study did not use a formal NAS scoring system but used clinical decision to titrate dosage based on the presence of tremors, increased flexor tone, rigidity of such severity not abated by swaddling, and regurgitation with feeding (<a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). A single study which compared morphine versus phenobarbital did not titrate dose of treatment according to severity of withdrawal (<a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>). </p> <p>Seven studies did not report second line treatment used when allocated first treatment drug failed to control NAS (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). Five studies reported second line treatments that were different to primary study interventions including clonazepam (<a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>), chloral hydrate (<a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>), and phenobarbital (<a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>). Four studies used the alterative primary study treatment when allocated treatment failed (<a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). </p> <section id="CD002059-sec-0048"> <h6 class="title">Opioid plus supportive treatment versus supportive treatment</h6> <p>A single study compared oral morphine 0.5 mg/kg/day in four to six divided doses titrated to NAS score up to maximum 0.9 mg/kg/day to non‐pharmacologic treatment with supportive comfort measures (included pacifier, swaddling, close wrapping, small frequent feeds, close skin contact by carrying in sling, warm bath and any other method to maintain the neonate in a calm state) (<a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>). </p> </section> <section id="CD002059-sec-0049"> <h6 class="title">Opioid versus opioid</h6> <p>Six studies compared one opioid to another opioid (<a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>). Two studies compared oral morphine to oral methadone (<a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>). In both studies, the dosage regimen and weaning schedule of study medications were the same in both intervention groups. For <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>, infants with Finnegan scores of 12 or less were administered 0.05 mg/kg every four hours. Infants with Finnegan scores above 12 were administered 0.1 mg/kg every four hours. Dosage was increased by 0.05 mg/kg/dose until a Finnegan score of 8 or more was reached, to a maximum of 0.2 mg/kg/dose. Weaning was by 10% of initial stabilising dose. For <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>, infants with two consecutive Finnegan scores of 8 or more, or one of 12, received 0.3 mg/kg titrated up to a maximum 0.9 mg/kg/day. Study drug was decreased by 10% every 12 to 48 hours with a score below 8, and treatment stopped at 20% of the initial dose. Morphine was divided into four hourly doses, and methadone into eight hourly doses. </p> <p>Three studies, which restricted enrolment to infants of mothers using only opioids, compared oral morphine to sublingual buprenorphine (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). The <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a> sublingual buprenorphine regimen commenced at 13.2 μg/kg per day in three divided doses with dose titration by 20% per day to a maximum of 39 μg/kg/day. Weaning was commenced when infants had a Finnegan score of less than 8 for at least three days, with a reduction of buprenorphine dosage by 10% daily and cessation when at or near initial dose. The morphine regimen commenced at 0.4 mg/kg/day in six divided doses with subsequent dose titration by 10% per day according to Finnegan score to a maximum of 1 mg/kg/day. Weaning was commenced when infants had a Finnegan score of less than 8 for at least three days, with a reduction of morphine dosage by 10% daily as tolerated. The <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a> and <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a> studies' buprenorphine regimens commenced at 15.9 μg/kg per day in three divided doses with dose titration by 20% per day to a maximum of 60 μg/kg/day. The morphine regimens in all three Kraft studies (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>), commenced at 0.4 mg/kg/day and were titrated by 20% to a maximum 1 mg/kg/day in two studies according to the Finnegan score (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>), and 1.2 mg/kg/day in the other according to the MOTHER NAS score (<a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). Weaning was with a reduction of morphine dosage by 10% daily as tolerated. </p> <p>One study compared oral morphine to oral dilute tincture of opium (DTO) with an initial morphine dose equivalent of 0.192 mg/kg/day for both treatments (<a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>). The dose of each was increased by two drops per dose until infants had a Finnegan score of 8 or less, or the mean of three consecutive scores was 7 or less. Weaning of both treatments followed 72 hours of NAS control and involved decreasing the control dose by 10% each day. </p> </section> <section id="CD002059-sec-0050"> <h6 class="title">Opioid versus phenobarbital</h6> <p>Nine studies compared an opioid to phenobarbital (<a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). </p> <p>Four studies (<a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>), compared oral paregoric to either oral or intramuscular phenobarbital. <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> and <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> compared an unreported dose of oral paregoric to an oral phenobarbital regimen with or without a loading dose regimen (20 mg/kg). Maintenance phenobarbital dose was 5 mg/kg/day titrated up to 10 mg/kg/day according to NAS scores. The phenobarbital regimens were combined in the reports so are reported combined in this review. <a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a> compared oral paregoric 0.42 mL/kg/day titrated up to 2.1 mL/kg/day (equivalent of 0.17 mg/kg/day to 0.84 mg/kg/day of morphine) to oral phenobarbital 5 mg/kg/day titrated up to 16 mg/kg/day. <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a> compared an initial dose of oral paregoric 0.2 mL every three hours (equivalent of 0.65 mg/kg/day of morphine) increased by 0.05 mL/dose, to an intramuscular dose of phenobarbital 5 mg/kg/day increased by 1 mg/kg/day. The maximum dose was not reported. </p> <p><a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> compared methadone 0.25 mg every six hours increased to a maximum of 0.5 mg every six hours to phenobarbital 5 mg/kg/day titrated up to 8 mg/kg/day 'tailored day to day' by the clinician. </p> <p>Four studies compared oral morphine to either oral or intramuscular phenobarbital. <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a> compared oral morphine 50 μg/kg/dose every four hours to oral phenobarbital 2 mg/kg every six hours without dose titration. <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a> compared oral morphine 0.5 mg/kg/day titrated up to maximum 0.9 mg/kg/day to phenobarbital given as a loading dose 15 mg/kg intramuscularly then 6 mg/kg/day titrated up to maximum 10 mg/kg/day. <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a> compared oral morphine 0.24 mg/kg/day to a loading dose of intramuscular phenobarbital 20 mg/kg with a further dose of 5 mg/kg given at 8‐ to 12‐hour intervals titrated to a maximum of 40 mg/kg. <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> compared morphine starting dose 0.25 mg/kg four hourly to maximal 0.5 mg/kg four hourly, to phenobarbital loading dose 10 mg/kg with maintenance 0.83 mg/kg four hourly to maximum 1.66 mg/kg four hourly. </p> </section> <section id="CD002059-sec-0051"> <h6 class="title">Opioid versus diazepam</h6> <p>Three studies compared an opioid to diazepam (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). Two studies compared paregoric to diazepam titrated according to Finnegan score but did not report on the doses used (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>). One study compared methadone 0.25 mg every six hours increased to a maximum of 0.5 mg every six hours to diazepam 0.5 mg every eight hours titrated up to maximum 2 mg/kg every eight hours (<a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). </p> </section> <section id="CD002059-sec-0052"> <h6 class="title">Opioid versus clonidine</h6> <p>A single study compared oral morphine at an initial dose of 0.4 mg/kg/day titrated up to a maximum 1 mg/kg/day, to oral clonidine at an initial dose of 5 μg/kg/day in eight divided doses titrated up to a maximum of 12 μg/kg/day (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>). </p> </section> <section id="CD002059-sec-0053"> <h6 class="title">Opioid versus chlorpromazine</h6> <p>A single study compared morphine starting dose 0.25 mg/kg four hourly to maximal 0.5 mg/kg four hourly, to chlorpromazine starting dose 0.5 mg/kg four hourly to maximal 1 mg/kg four hourly (<a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). </p> </section> </section> <section id="CD002059-sec-0054"> <h5 class="title">Primary outcomes</h5> <p>No study reported neonatal or infant mortality.</p> <p>Three studies reported neurodevelopmental outcomes (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>), but none reported neurodevelopmental disability. <a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> reported longer term neurodevelopmental outcome using the Bayley Scales III and Preschool Language Scale IV at one year of age according to treatment allocated. <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a> reported the Mental Disability Index (MDI) and Physical Disability Index (PDI) at 18 months using the Bayley III Neurodevelopmental Assessment. <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> reported the Bayley MDI at six months according to treatment received (not allocated). </p> <p>Eight studies reported treatment failure (<a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>). As <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> may have reported some of the same infants as <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>, only data from <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> are used in this review. Ten studies reporting treatment failure used a standardised NAS score to determine response to treatment (<a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported the need for a second agent but did not use a standardised score. Six studies reported clinical seizures (<a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a> reported clinical seizures in 12 infants with subsequent abnormal electroencephalogram (EEG) in 10 of these. <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a> reported infants who developed myoclonic jerks with no infant being diagnosed with a clinical seizure or a seizure confirmed on EEG. No study routinely performed an EEG or EEG monitoring. </p> </section> <section id="CD002059-sec-0055"> <h5 class="title">Secondary outcomes</h5> <p>These were all incompletely reported. The most commonly reported outcomes were days hospitalisation (nine studies), and days pharmacologic treatment (12 studies). Two studies reported days of admission to a newborn nursery (<a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>). Of the two studies that provided data concerning infant growth, one study measured weight gain per day for the duration of treatment (<a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>), and the other, time taken to regain birthweight (<a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>). Only one study reported standardised growth parameters at 12 months of age (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>). </p> <p>Four studies reported continuous outcomes as non‐parametric data requiring conversion to parametric data for inclusion in analysis. <a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a> and <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a> reported days of pharmacologic treatment as median and range. <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a> reported median days hospitalisation with 95% confidence intervals, and <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported median days treatment with 95% confidence intervals. <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a> also reported treatment failure as percentages of allocated group requiring conversion. </p> </section> </section> <section id="CD002059-sec-0056"> <h4 class="title">Excluded studies</h4> <p>We excluded 52 studies (55 reports). See <a href="./references#CD002059-sec-0155" title="">Characteristics of excluded studies</a> for reasons for exclusion. </p> <section id="CD002059-sec-0057"> <h5 class="title">Studies awaiting classification</h5> <p>Four studies are awaiting classification, completed but with no publication to date (<a href="./references#CD002059-bbs2-0068" title="IRCT20181231042183N1. Assessment effect of bopronorphin neonates with obstinence syndrom [Comparison bopronorphin and morphin among neonates with obstinence syndrom admitted In Birjand Vali-asr Hospital]. en.irct.ir/trial/36431 (first received 18 January 2019). ">IRCT20181231042183N1</a>; <a href="./references#CD002059-bbs2-0069" title="NCT01671410. Buprenorphine for treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines (MOPPlus) [A randomized, open label clinical trial of buprenorphine in the treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines or are breastfeeding]. clinicaltrials.gov/ct2/show/NCT01671410 (first received 23 August 2012). ">NCT01671410</a>; <a href="./references#CD002059-bbs2-0070" title="NCT01708707. A randomized comparison of sublingual buprenorphine to morphine sulfate in the treatment of neonatal abstinence syndrome (NAS) [Comparison of buprenorphine to morphine in treatment of neonatal abstinence syndrome (NAS)]. clinicaltrials.gov/ct2/show/nct01708707 (first received 17 October 2012). ">NCT01708707</a>; <a href="./references#CD002059-bbs2-0071" title="NCT01723722. Treatment of Neonatal Abstinence Syndrome (HOMENOW) [Treatment of neonatal abstinence syndrome: evaluation of efficacy of phenobarbital in combination with either methadone or diluted deodorized tincture of opium as stabilizing and tapering regiments]. clinicaltrials.gov/ct2/show/NCT01723722 (first received 8 November 2012). ">NCT01723722</a>). Two of these four studies were stopped early (<a href="./references#CD002059-bbs2-0069" title="NCT01671410. Buprenorphine for treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines (MOPPlus) [A randomized, open label clinical trial of buprenorphine in the treatment of neonatal abstinence syndrome in infants with in utero exposure to benzodiazepines or are breastfeeding]. clinicaltrials.gov/ct2/show/NCT01671410 (first received 23 August 2012). ">NCT01671410</a>; <a href="./references#CD002059-bbs2-0070" title="NCT01708707. A randomized comparison of sublingual buprenorphine to morphine sulfate in the treatment of neonatal abstinence syndrome (NAS) [Comparison of buprenorphine to morphine in treatment of neonatal abstinence syndrome (NAS)]. clinicaltrials.gov/ct2/show/nct01708707 (first received 17 October 2012). ">NCT01708707</a>). See <a href="./references#CD002059-sec-0156" title="">Characteristics of studies awaiting classification</a> for details. </p> </section> <section id="CD002059-sec-0058"> <h5 class="title">Ongoing studies</h5> <p>Six studies are ongoing (<a href="./references#CD002059-bbs2-0077" title="NCT04455802. Randomized control trial of buprenorphine vs. morphine for the treatment of neonatal opioid withdrawal syndrome (NOWS) [Prospective randomized blinded trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS)]. clinicaltrials.gov/ct2/show/NCT04455802 (first received 2 July 2020). ">NCT04455802</a>; <a href="./references#CD002059-bbs2-0075" title="NCT04214834. Trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS) [Pragmatic, randomized, blinded trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS)]. clinicaltrials.gov/ct2/show/NCT04214834 (first received 2 January 2020). ">NCT04214834</a>; <a href="./references#CD002059-bbs2-0074" title="NCT04104646. CHF6563 in babies with neonatal opioid withdrawal syndrome [A phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with neonatal opioid withdrawal syndrome]. clinicaltrials.gov/ct2/show/NCT04104646 (first received 26 September 2019). ">NCT04104646</a>; <a href="./references#CD002059-bbs2-0073" title="NCT03092011. Treatment of neonatal abstinence syndrome with clonidine versus morphine as primary therapy. clinicaltrials.gov/show/NCT03092011 (first received 27 March 2017). ">NCT03092011</a>; <a href="./references#CD002059-bbs2-0072" title="NCT02851303. Morphine versus methadone for opiate exposed infants with neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT02851303 (first received 1 August 2016). ">NCT02851303</a>; <a href="./references#CD002059-bbs2-0076" title="NCT04298853. Optimal morphine dosing schedule for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT04298853 (first received 6 March 2020). ">NCT04298853</a>). See <a href="./references#CD002059-sec-0157" title="">Characteristics of ongoing studies</a> for details. </p> </section> </section> </section> <section id="CD002059-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD002059-sec-0154" title="">Characteristics of included studies</a> for risk of bias assessments and risk of bias summary (<a href="#CD002059-fig-0003">Figure 3</a>). Overall, we considered six studies to be at low risk of bias (adequate randomisation and allocation concealment, blinding of treatment and greater than 90% follow‐up) (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>). However, we considered <a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> at high risk of bias for long‐term outcomes due to incomplete reporting. We judged <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> to be at low risk of bias for the outcome of treatment failure. However, for other outcomes, we considered <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> to be at high risk of bias due to incomplete reporting. </p> <div class="figure" id="CD002059-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD002059-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD002059-sec-0060"> <h4 class="title">Allocation</h4> <p>We assessed 10 studies as having a low risk of selection bias as they reported a computer‐generated method of random sequencing with treatment allocation adequately concealed (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). We assessed the remaining six studies as having either high or unclear risk of bias. Three of these reported random allocation to treatment but did not report method of sequence generation (<a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). The other three studies used quasi‐random methods of participant allocation (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>). <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> and <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> communicated “drug assignment pulled from envelopes which were designated according to first letter of last name”. <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a> designated treatment according to the last number of the infant's hospital number. Several studies had sizeable and unexplained differences in numbers of infants allocated to each group (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>). <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> communicated that an interim analysis found the diazepam group had excessive complications (somnolence and respiratory depression), so enrolment in this group was stopped. </p> </section> <section id="CD002059-sec-0061"> <h4 class="title">Blinding</h4> <p>We assessed seven studies as having a low risk of performance and detection bias as solutions of identical appearance or placebo, or both, and a standardised treatment regimen were used (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). All other studies were considered at high risk of performance and detection bias as treatment interventions were not blinded with different treatment regimens between groups. </p> </section> <section id="CD002059-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed 11 studies as having a low risk of attrition bias (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>). However, for specific outcomes, <a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> reported 23% lost to one year follow‐up, so we considered this study at high risk for long‐term outcomes; and <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a> reported that nine (8%) infants did not have data available for days to regain birthweight. We assessed four studies as at unclear risk of attrition bias. <a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a> had insufficient reporting detail to determine if seven infants with withdrawal signs too mild to require treatment were randomised to treatment. Three studies did not report numbers enrolled, so losses are unknown (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>). <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported all infants for the outcomes of treatment failure, seizures and adverse events but did not report 16% of infants for other outcomes. </p> </section> <section id="CD002059-sec-0063"> <h4 class="title">Selective reporting</h4> <p>Six studies prospectively registered trials which provided prespecified outcomes, so we considered these to be at low risk of bias (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). Two studies were prospectively registered (<a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>), so we judged these to be at unclear risk of bias. Protocols or trial registrations were not available for the other nine studies, so we consider the risk of reporting bias for these to be unclear. </p> </section> <section id="CD002059-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> reported baseline differences in prenatal drug exposures between groups. <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a> reported a significant difference in maternal methadone dose between groups. <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> reported asymmetric group sizes and different proportions of infants in groups with antenatal exposure to multiple drugs, but did not report other demographics. <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a> reported that infants allocated to phenobarbital tended to have been exposed to benzodiazepines and other classes of drugs more often than those allocated to morphine. <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a> also reported asymmetrical group sizes. <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> had asymmetrical group sizes and did not report demographics. <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a> reported baseline differences in demographics between groups. <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a> had asymmetrical group sizes and reported some baseline differences in demographics. <a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a> reported some imbalance in gender distribution between groups. <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> did not report baseline characteristics of groups. </p> <p>Seven studies were assessed as having no other potential sources of bias (<a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). </p> </section> </section> <section id="CD002059-sec-0065"> <h3 class="title" id="CD002059-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD002059-tbl-0001"><b>Summary of findings 1</b> Opioid versus placebo or no treatment / usual care for opioid withdrawal in newborn infants</a>; <a href="./full#CD002059-tbl-0002"><b>Summary of findings 2</b> Morphine versus methadone for opioid withdrawal in newborn infants</a>; <a href="./full#CD002059-tbl-0003"><b>Summary of findings 3</b> Morphine versus buprenorphine for opioid withdrawal in newborn infants</a>; <a href="./full#CD002059-tbl-0004"><b>Summary of findings 4</b> Morphine versus dilute tincture of opium for opioid withdrawal in newborn infants</a>; <a href="./full#CD002059-tbl-0005"><b>Summary of findings 5</b> Opioid versus clonidine for opioid withdrawal in newborn infants</a>; <a href="./full#CD002059-tbl-0006"><b>Summary of findings 6</b> Opioid versus diazepam for opioid withdrawal in newborn infants</a>; <a href="./full#CD002059-tbl-0007"><b>Summary of findings 7</b> Opioid versus phenobarbital for opioid withdrawal in newborn infants</a>; <a href="./full#CD002059-tbl-0008"><b>Summary of findings 8</b> Opioid versus chlorpromazine for opioid withdrawal in newborn infants</a> </p> <section id="CD002059-sec-0066"> <h4 class="title">Comparison 1. Opioid versus placebo or no treatment / usual care (all infants)</h4> <p>A single study compared morphine plus supportive care to supportive care alone (<a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>). See <a href="./full#CD002059-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD002059-sec-0067"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002059-fig-0004" title="">Analysis 1.1</a>; <a href="./references#CD002059-fig-0005" title="">Analysis 1.2</a>) </p> <p><a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a> reported no difference in treatment failure (RR 1.29, 95% CI 0.41 to 4.07; 80 infants; very low certainty evidence). There were no infants with seizures (80 participants; very low certainty evidence). <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a> did not report neonatal or infant mortality, neurodevelopmental disability and adverse events. </p> </section> <section id="CD002059-sec-0068"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002059-fig-0006" title="">Analysis 1.3</a>; <a href="./references#CD002059-fig-0007" title="">Analysis 1.4</a>; <a href="./references#CD002059-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD002059-fig-0009" title="">Analysis 1.6</a>; <a href="./references#CD002059-fig-0010" title="">Analysis 1.7</a>) </p> <p><a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a> reported an increase in days hospitalisation (MD 15.00, 95% CI 8.86 to 21.14; 80 infants; very low certainty evidence), and days treatment (MD 12.50, 95% CI 7.52 to 17.48; 80 infants; very low certainty evidence) for infants treated with an opioid and supportive care compared to supportive care alone. Infants receiving opioid and supportive care had a reduction in days to regain birthweight (MD ‐2.80, 95% CI ‐5.33 to ‐0.27; 72 infants), an increase in days in special care nursery (MD 16.70, 95% CI 10.67 to 22.73; 80 infants), and a reduction in duration of supportive care (MD ‐197.20 minutes/day, 95% CI ‐274.15 to ‐120.25; 80 infants) compared to infants who received supportive care alone. </p> <p>No studies reported diluted tincture of opium, paregoric, methadone or buprenorphine versus placebo or no treatment / usual care. </p> </section> </section> <section id="CD002059-sec-0069"> <h4 class="title">Comparison 2. Opioid versus another opioid (all infants)</h4> <p>Two studies compared morphine to methadone (<a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>). </p> <p>Three studies compared morphine to sublingual buprenorphine (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). </p> <p>One study compared morphine to diluted tincture of opium (<a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>). </p> <p>See <a href="./full#CD002059-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002059-tbl-0003">summary of findings Table 3</a>; and <a href="./full#CD002059-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD002059-sec-0070"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002059-fig-0011" title="">Analysis 2.1</a>; <a href="./references#CD002059-fig-0012" title="">Analysis 2.2</a>) </p> <section id="CD002059-sec-0071"> <h6 class="title">Morphine versus methadone</h6> <p>Data from two studies showed no difference in treatment failure (RR 1.59, 95% CI 0.95 to 2.67; I<sup>2</sup> = 0%; 147 infants; low certainty evidence) in infants treated with morphine compared to methadone (<a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>). Neither study reported neonatal or infant mortality, neurodevelopmental disability and adverse events. </p> </section> <section id="CD002059-sec-0072"> <h6 class="title">Morphine versus sublingual buprenorphine</h6> <p>Data from three studies showed no difference in treatment failure (RR 0.79, 95% CI 0.36 to 1.74; I<sup>2</sup> = 42%; 113 infants; very low certainty evidence) or seizures (RR 0.33, 95% CI 0.01 to 7.50; I<sup>2</sup> = 0%; 113 infants; very low certainty evidence) (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). These studies did not report neonatal or infant mortality and neurodevelopmental disability. </p> </section> <section id="CD002059-sec-0073"> <h6 class="title">Morphine versus diluted tincture of opium</h6> <p><a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a> did not report treatment failure, neonatal or infant mortality, neurodevelopmental disability and adverse events. </p> </section> </section> <section id="CD002059-sec-0074"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002059-fig-0013" title="">Analysis 2.3</a>; <a href="./references#CD002059-fig-0014" title="">Analysis 2.4</a>; <a href="./references#CD002059-fig-0015" title="">Analysis 2.5</a>; <a href="./references#CD002059-fig-0016" title="">Analysis 2.6</a>; <a href="./references#CD002059-fig-0017" title="">Analysis 2.7</a>; <a href="./references#CD002059-fig-0018" title="">Analysis 2.8</a>; <a href="./references#CD002059-fig-0019" title="">Analysis 2.9</a>; <a href="./references#CD002059-fig-0020" title="">Analysis 2.10</a>; <a href="./references#CD002059-fig-0021" title="">Analysis 2.11</a>) </p> <section id="CD002059-sec-0075"> <h6 class="title">Morphine versus methadone</h6> <p><a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a> reported no difference in days hospitalisation (MD 1.40, 95% CI ‐3.08 to 5.88; 116 infants; low certainty evidence). Data from two studies found an increase in days treatment (MD 2.71, 95% CI 0.22 to 5.21; 147 infants; I<sup>2</sup> = 54%; low certainty evidence) for infants treated with morphine compared to methadone (<a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>). <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a> reported no difference in exclusive or partial breastfeeding (RR 0.72, 95% CI 0.51 to 1.02; 116 infants), weight gain (MD 2.80, 95% CI ‐2.31 to 7.91; 116 infants), adverse events (RR 0.33, 95% CI 0.01 to 8.02; 116 infants; low certainty evidence), out of home placement (RR 1.31, 95% CI 0.54 to 3.14; 83 infants), Bayley III composite score (MD ‐2.00, 95% CI ‐10.31 to 6.31; 83 infants), language composite score (MD ‐1.80, 95% CI ‐9.46 to 5.86; 83 infants), or motor composite score (MD ‐4.30, 95% CI ‐11.77 to 3.17; 83 infants). </p> </section> <section id="CD002059-sec-0076"> <h6 class="title">Morphine versus sublingual buprenorphine</h6> <p>Data from three studies showed an increase in days hospitalisation (MD 11.45, 95% CI 5.89 to 17.01; I<sup>2</sup> = 0%; 113 infants; moderate certainty evidence) and days treatment (MD 12.79, 95% CI 7.57 to 18.00; I<sup>2</sup> = 0%; 112 infants; moderate certainty evidence) for infants treated with morphine compared to sublingual buprenorphine (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). A single adverse event (seizure) was reported in infants exposed to buprenorphine (3 studies, 113 participants; very low certainty evidence). </p> </section> <section id="CD002059-sec-0077"> <h6 class="title">Morphine versus diluted tincture of opium</h6> <p><a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a> reported no difference in days hospitalisation (MD 5.10, 95% CI ‐2.08 to 12.28; 33 infants; low certainty evidence), days treatment (MD 2.90, 95% CI ‐5.22 to 11.02; 33 infants; low certainty evidence) or weight gain (MD 3.50, 95% CI ‐6.23 to 13.23; 33 infants) for infants treated with morphine compared to diluted tincture of opium. </p> <p><a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a> reported no difference in Finnegan mean score, maximum score, days with mean score above 8, and area under the curve for score above 8. </p> <p>No studies reported the following opioid comparisons: morphine versus paregoric; diluted tincture of opium versus paregoric, methadone or buprenorphine; and methadone versus paregoric or buprenorphine. </p> </section> </section> </section> <section id="CD002059-sec-0078"> <h4 class="title">Comparison 3. Opioid versus another opioid (infants of mothers using only opioids)</h4> <p>Three studies compared morphine to sublingual buprenorphine in infants of mothers using only opioids (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). </p> <section id="CD002059-sec-0079"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002059-fig-0022" title="">Analysis 3.1</a>; <a href="./references#CD002059-fig-0023" title="">Analysis 3.2</a>) </p> <p>Analysis of the three studies showed no difference in treatment failure (RR 0.79, 95% CI 0.36 to 1.74; I<sup>2</sup> = 42%; 113 infants) or seizures (RR 0.33, 95% CI 0.01 to 7.50; I<sup>2</sup> = 0%; 3 studies, 113 infants) in infants treated with morphine compared to sublingual buprenorphine (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). These studies did not report neonatal or infant mortality and neurodevelopmental disability. </p> </section> <section id="CD002059-sec-0080"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002059-fig-0024" title="">Analysis 3.3</a>; <a href="./references#CD002059-fig-0025" title="">Analysis 3.4</a>) </p> <p>Analysis of the three studies showed an increase in days hospitalisation (MD 11.45, 95% CI 5.89 to 17.01; I<sup>2</sup> = 0%; 113 infants) and days treatment (MD 12.83, 95% CI 7.57 to 18.08; I<sup>2</sup> = 0%; 112 infants) in infants treated with morphine compared to sublingual buprenorphine (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). </p> <p>No other studies reported opioid comparisons used in the treatment of NAS in infants of mothers using only opioids. </p> </section> </section> <section id="CD002059-sec-0081"> <h4 class="title">Comparison 4. Opioid versus clonidine (all infants)</h4> <p>One study compared infants treated with morphine to infants treated with clonidine (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>). See <a href="./full#CD002059-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD002059-sec-0082"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002059-fig-0026" title="">Analysis 4.1</a>) </p> <p><a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> reported no treatment failures in either group (31 infants; low certainty evidence). This study did not report seizures, neonatal or infant mortality and neurodevelopmental disability. </p> </section> <section id="CD002059-sec-0083"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002059-fig-0027" title="">Analysis 4.2</a>; <a href="./references#CD002059-fig-0028" title="">Analysis 4.3</a>; <a href="./references#CD002059-fig-0029" title="">Analysis 4.4</a>; <a href="./references#CD002059-fig-0030" title="">Analysis 4.5</a>; <a href="./references#CD002059-fig-0031" title="">Analysis 4.6</a>; <a href="./references#CD002059-fig-0032" title="">Analysis 4.7</a>; <a href="./references#CD002059-fig-0033" title="">Analysis 4.8</a>) </p> <p><a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> reported no difference in days hospitalisation (MD 6.10, 95% CI ‐0.78 to 12.98; 31 infants; low certainty evidence) or days treatment (MD 10.70, 95% CI ‐2.76 to 24.16; 31 infants; low certainty evidence). <a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> reported no difference in Bayley III cognitive score (MD ‐0.40, 95% CI ‐6.66 to 5.86; 24 infants) or Bayley III motor score (MD 1.80, 95% CI ‐5.36 to 8.96; 24 infants) at 12 months. This study did not report adverse events. </p> <p><a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> reported no difference in weight (kg) (MD 0.40, 95% CI ‐0.53 to 1.33; 24 infants), length (cm) (MD ‐0.50, 95% CI ‐2.97 to 1.97; 24 infants) or head circumference (cm) (MD ‐0.10, 95% CI ‐1.10 to 0.90; 24 infants) at 12 months follow‐up. </p> <p><a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> also reported no significant difference between groups in Finnegan scores at 48 hours, 7 days and 14 days. This study did not report time to control of NAS. </p> </section> </section> <section id="CD002059-sec-0084"> <h4 class="title">Comparison 5. Opioid versus diazepam (all infants)</h4> <p>Two studies compared paregoric to diazepam, but as the studies may include some of the same infants, they have not been combined in meta‐analyses (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0007" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>). One study compared methadone to diazepam (<a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). See <a href="./full#CD002059-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD002059-sec-0085"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002059-fig-0034" title="">Analysis 5.1</a>) </p> <section id="CD002059-sec-0086"> <h6 class="title">Paregoric versus diazepam</h6> <p><a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> reported a significant reduction in treatment failure (RR 0.36, 95% CI 0.18 to 0.69; 52 infants) in infants treated with paregoric compared to diazepam. This study did not report seizures, neonatal or infant mortality and neurodevelopmental disability. </p> </section> <section id="CD002059-sec-0087"> <h6 class="title">Methadone versus diazepam</h6> <p><a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported no difference in treatment failure (RR 2.68, 95% CI 0.12 to 61.58; 34 infants). This study did not report seizures, neonatal or infant mortality and neurodevelopmental disability. </p> </section> <section id="CD002059-sec-0088"> <h6 class="title">Opioid versus diazepam</h6> <p>Data from <a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> and <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> showed a reduction in treatment failure (RR 0.43, 95% CI 0.23 to 0.80; I<sup>2</sup> = 37%; 2 studies, 86 infants; low certainty evidence) from use of an opioid compared to diazepam. The test for subgroup differences according to type of opioid used was not significant (P = 0.22; I<sup>2</sup> = 34.4%). </p> </section> </section> <section id="CD002059-sec-0089"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002059-fig-0035" title="">Analysis 5.2</a>; <a href="./references#CD002059-fig-0036" title="">Analysis 5.3</a>) </p> <p>Data for secondary outcomes were only available for the comparison methadone versus diazepam. </p> <section id="CD002059-sec-0090"> <h6 class="title">Methadone versus diazepam</h6> <p><a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported no difference in days hospitalisation (MD 4.38, 95% CI ‐1.26 to 10.02; 34 infants; very low certainty evidence) or days treatment (MD 1.56, 95% CI ‐1.59 to 4.71; 33 infants; very low certainty evidence). This study did not report adverse events. </p> </section> </section> </section> <section id="CD002059-sec-0091"> <h4 class="title">Comparison 6. Opioid versus diazepam (infants of mothers using only opioids)</h4> <p>One study compared paregoric to diazepam in infants of mothers using only opioids (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>). </p> <section id="CD002059-sec-0092"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002059-fig-0037" title="">Analysis 6.1</a>; <a href="./references#CD002059-fig-0037" title="">Analysis 6.1</a>) </p> <p><a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> reported a reduction in treatment failure (RR 0.11, 95% CI 0.02 to 0.51; 19 infants) in infants treated with paregoric compared to diazepam. This study did not report seizures, neonatal or infant mortality and neurodevelopmental disability. </p> </section> <section id="CD002059-sec-0093"> <h5 class="title">Secondary outcomes</h5> <p>None reported.</p> </section> </section> <section id="CD002059-sec-0094"> <h4 class="title">Comparison 7. Opioid versus phenobarbital (all infants)</h4> <p>Four studies compared morphine to phenobarbital (<a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). Two studies compared paregoric to phenobarbital (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>). One study compared methadone to phenobarbital (<a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). See <a href="./full#CD002059-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD002059-sec-0095"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002059-fig-0038" title="">Analysis 7.1</a>; <a href="./references#CD002059-fig-0040" title="">Analysis 7.3</a>) </p> <section id="CD002059-sec-0096"> <h6 class="title">Opioid versus phenobarbital</h6> <p>Overall, data from six studies showed a reduction in treatment failure (RR 0.59, 95% CI 0.41 to 0.86; I<sup>2</sup> = 32%; 452 infants; moderate certainty evidence) for infants receiving an opioid (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). The test for subgroup differences was not significant (P = 0.14, I<sup>2</sup> = 49.8%). Data from three studies found no difference in seizures (RR 0.08, 95% CI 0.00 to 1.44; I<sup>2</sup> = 100%; 3 studies, 281 infants; very low certainty evidence) between groups (<a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>), although only a single study reported any infants with seizures, all in the phenobarbital group (<a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>). </p> </section> <section id="CD002059-sec-0097"> <h6 class="title">Morphine versus phenobarbital</h6> <p>Data from four studies showed a reduction in treatment failure (RR 0.46, 95% CI 0.30 to 0.73; I<sup>2</sup> = 44%; 299 infants) in infants treated with morphine compared to phenobarbital (<a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). Subgroup analysis according to dose of morphine used found a reduction in treatment failure for studies using morphine 0.5 mg/kg/day or more (RR 0.29, 95% CI 0.13 to 0.61; I<sup>2</sup> = 32%; 3 studies, 224 infants) (<a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>), but no difference for a single study using morphine 0.3 mg/kg/day with no titration (RR 0.73, 95% CI 0.42 to 1.26; 75 infants) (<a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>), with the test for subgroup difference significant (P = 0.05, I<sup>2</sup> = 73.5%). Data from two studies found no seizure event in either group (164 infants) (<a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). These studies did not report neonatal or infant mortality and neurodevelopmental disability. </p> </section> <section id="CD002059-sec-0098"> <h6 class="title">Paregoric versus phenobarbital</h6> <p><a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> reported no difference in treatment failure (RR 1.09, 95% CI 0.53 to 2.22; 119 infants). <a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a> reported a reduction in seizures of borderline significance (RR 0.08, 95% CI 0.00 to 1.44; 111 infants; RD ‐0.11, 95% CI ‐0.20 to ‐0.03) in infants receiving paregoric compared to phenobarbital. All seizures (n = 7) occurred in the phenobarbital group. These studies did not report neonatal or infant mortality and neurodevelopmental disability. </p> </section> <section id="CD002059-sec-0099"> <h6 class="title">Methadone versus phenobarbital</h6> <p><a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported no difference in treatment failure (RR 0.89, 95% CI 0.06 to 13.08; 34 infants). This study did not report seizures, neonatal or infant mortality and neurodevelopmental disability. </p> </section> </section> <section id="CD002059-sec-0100"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002059-fig-0041" title="">Analysis 7.4</a>; <a href="./references#CD002059-fig-0042" title="">Analysis 7.5</a>; <a href="./references#CD002059-fig-0043" title="">Analysis 7.6</a>; <a href="./references#CD002059-fig-0044" title="">Analysis 7.7</a>; <a href="./references#CD002059-fig-0045" title="">Analysis 7.8</a>; <a href="./references#CD002059-fig-0046" title="">Analysis 7.9</a>; <a href="./references#CD002059-fig-0047" title="">Analysis 7.10</a>) </p> <section id="CD002059-sec-0101"> <h6 class="title">Opioid versus phenobarbital</h6> <p>Data from three studies found no difference in days hospitalisation between groups (MD ‐0.62, 95% CI ‐2.97 to 1.74; I<sup>2</sup> = 3%; 166 infants; very low certainty evidence) (<a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>). Data from six studies found no difference in days treatment between groups (MD 1.01, 95% CI ‐0.48 to 2.50; I<sup>2</sup> = 72%; 348 infants; low certainty evidence) (<a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported no adverse events in either group (90 infants; low certainty evidence). </p> </section> <section id="CD002059-sec-0102"> <h6 class="title">Morphine versus phenobarbital</h6> <p>Data from two studies found no difference in days hospitalisation between groups (MD ‐0.59, 95% CI ‐3.18 to 2.00; I<sup>2</sup> = 51%; 134 infants) (<a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>). Data from four studies found no difference in days treatment between groups (MD ‐0.97, 95% CI ‐3.07 to 1.12; I<sup>2</sup> = 38%; 285 infants) (<a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>; <a href="./references#CD002059-bbs2-0015" title="IRCT201406239568N8. Comparison of phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized controlled trial. en.irct.ir/trial/10133 (first received 12 July 2014). NayeriF , SheikhS , KalaniM , NiknafsP , ShariatM , DaliliH , et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatrics2015;15(57):no pagination. [DOI: 10.1186/s12887-015-0377-9.] [IRCT201406239568N8] [PMID: 25976238]">Nayeri 2015</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a> reported no difference between groups in days to regain birthweight (MD ‐1.40, 95% CI ‐3.47 to 0.67; 71 infants), days in special care nursery (MD ‐6.40, 95% CI ‐13.81 to 1.01; 74 infants) or duration of supportive care (minutes/day) (MD ‐1.40, 95% CI ‐3.47 to 0.67; 71 infants). <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported no adverse events in either group (90 infants). <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a> reported a reduction in admissions to the nursery (RR 0.47, 95% CI 0.27 to 0.82; 75 infants) for infants treated with morphine compared to phenobarbital. </p> </section> <section id="CD002059-sec-0103"> <h6 class="title">Paregoric versus phenobarbital</h6> <p><a href="./references#CD002059-bbs2-0003" title="CarinI , GlassL , ParekhA , SolomonN , SteigmanJ , WongS . Neonatal methadone withdrawal. Effect of two treatment regimens. American Journal of Diseases of Children1983;137(12):1166-9. [DOI: 10.1001/archpedi.1983.02140380026008] [PMID: 6416059]">Carin 1983</a> reported an increase in days treatment (MD 4.25, 95% CI 1.92 to 6.58; 31 infants) for infants treated with paregoric compared to phenobarbital. </p> <p><a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a> reported no difference in Lipsitz scores for all except the 21‐day time point for infants on treatment over a 30‐day period. </p> </section> <section id="CD002059-sec-0104"> <h6 class="title">Methadone versus phenobarbital</h6> <p><a href="./references#CD002059-bbs2-0014" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127(2):199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported no difference in days hospitalisation (MD ‐0.74, 95% CI ‐6.37 to 4.89; 32 infants) or days treatment (MD ‐2.74, 95% CI ‐7.81 to 2.33; 32 infants) for infants treated with methadone compared with phenobarbital. </p> </section> </section> </section> <section id="CD002059-sec-0105"> <h4 class="title">Comparison 8. Opioid versus phenobarbital (infants of mothers using only opioids)</h4> <p><a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> compared opioid to phenobarbital in infants of mothers using only opioids. </p> <section id="CD002059-sec-0106"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002059-fig-0048" title="">Analysis 8.1</a>) </p> <p><a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a> reported a reduction in treatment failure (RR 0.14, 95% CI 0.02 to 0.98; 40 infants) for infants treated with an opioid compared to phenobarbital. No other outcomes were reported. </p> </section> </section> <section id="CD002059-sec-0107"> <h4 class="title">Comparison 9. Opioid versus chlorpromazine (all infants)</h4> <p><a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> compared morphine to chlorpromazine. See <a href="./full#CD002059-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD002059-sec-0108"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002059-fig-0049" title="">Analysis 9.1</a>; <a href="./references#CD002059-fig-0050" title="">Analysis 9.2</a>) </p> <p><a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported a reduction in treatment failure (RR 0.05, 95% CI 0.01 to 0.36; 96 infants; moderate certainty evidence) for infants receiving an opioid, and no seizures in either group (96 infants; low certainty evidence). </p> </section> <section id="CD002059-sec-0109"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002059-fig-0051" title="">Analysis 9.3</a>; <a href="./references#CD002059-fig-0052" title="">Analysis 9.4</a>) </p> <p><a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported no difference between groups in days treatment (MD ‐3.00, 95% CI ‐15.08 to 9.08; 77 infants; low certainty evidence) and no adverse events in either group (96 infants; low certainty evidence). </p> </section> </section> <section id="CD002059-sec-0110"> <h4 class="title">Comparison 10. Sensitivity analysis</h4> <p>We considered seven studies to be at low risk of bias (adequate randomisation and allocation concealment, blinding of treatment and greater than 90% follow‐up) (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>), although two studies had complete reporting only for short‐term outcomes (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>), and for treatment failure, seizures and adverse events (<a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). The results from these studies for the outcomes included in the GRADE certainty of evidence assessment (treatment failure; seizures; neonatal or infant mortality; neurodevelopmental disability; duration of hospitalisation (days); duration of treatment (days); adverse events) are reported below. </p> <p> <ol id="CD002059-list-0021"> <li> <p>Opioid versus placebo or no treatment / usual care (all infants): no studies.</p> </li> <li> <p>Opioid versus another opioid (all infants):</p> <ol id="CD002059-list-0022"> <li> <p>morphine versus methadone (<a href="./references#CD002059-fig-0053" title="">Analysis 10.1</a>; <a href="./references#CD002059-fig-0055" title="">Analysis 10.3</a>; <a href="./references#CD002059-fig-0056" title="">Analysis 10.4</a>; <a href="./references#CD002059-fig-0057" title="">Analysis 10.5</a>). Data from two studies found no difference between groups in treatment failure (RR 1.59, 95% CI 0.95 to 2.67; I<sup>2</sup> = 0%; 47 infants) and an increase in days treatment (MD 2.71, 95% CI 0.22 to 5.21; I<sup>2</sup> = 54%; 147 infants) for infants treated with morphine compared to methadone (<a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>). <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a> reported no difference between groups in days hospitalisation (MD 1.40, 95% CI ‐3.08 to 5.88; 116 infants). <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a> reported a single adverse event (apnoea, lethargy and hypothermia) in the methadone group. </p> </li> <li> <p>morphine versus buprenorphine (<a href="./references#CD002059-fig-0053" title="">Analysis 10.1</a>; <a href="./references#CD002059-fig-0054" title="">Analysis 10.2</a>; <a href="./references#CD002059-fig-0055" title="">Analysis 10.3</a>; <a href="./references#CD002059-fig-0056" title="">Analysis 10.4</a>; <a href="./references#CD002059-fig-0057" title="">Analysis 10.5</a>). <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a> reported no difference between groups in treatment failure (RR 1.54, 95% CI 0.55 to 4.34; 63 infants), no infant as having a seizure (63 infants), and an increase in days hospitalisation (MD 12.00, 95% CI 4.83 to 19.17; 63 infants) and days treatment (MD 13.00, 95% CI 5.71 to 20.29; 63 infants) for infants treated with morphine compared to buprenorphine. No infant was reported as having an adverse event (participants = 63). </p> </li> <li> <p>morphine versus diluted tincture of opium (<a href="./references#CD002059-fig-0055" title="">Analysis 10.3</a>; <a href="./references#CD002059-fig-0056" title="">Analysis 10.4</a>). <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a> reported no difference between groups in days hospitalisation (MD 5.10, 95% CI ‐2.08 to 12.28; 33 infants) or days treatment (MD 2.90, 95% CI ‐5.22 to 11.02; 33 infants). </p> </li> </ol> </li> <li> <p>Opioid versus clonidine (all infants):</p> <ol id="CD002059-list-0023"> <li> <p>morphine versus clonidine (<a href="./references#CD002059-fig-0053" title="">Analysis 10.1</a>; <a href="./references#CD002059-fig-0055" title="">Analysis 10.3</a>; <a href="./references#CD002059-fig-0056" title="">Analysis 10.4</a>). <a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a> reported no infants had treatment failure (31 infants), and no difference between groups in days hospitalisation (MD 6.10, 95% CI ‐0.78 to 12.98; 31 infants) or days treatment (MD 10.70, 95% CI ‐2.76 to 24.16; 31 infants). </p> </li> </ol> </li> <li> <p>Opioid versus diazepam (all infants): no studies.</p> </li> <li> <p>Opioid versus phenobarbital (all infants):</p> <ol id="CD002059-list-0024"> <li> <p>morphine versus phenobarbital (<a href="./references#CD002059-fig-0053" title="">Analysis 10.1</a>; <a href="./references#CD002059-fig-0054" title="">Analysis 10.2</a>; <a href="./references#CD002059-fig-0056" title="">Analysis 10.4</a>; <a href="./references#CD002059-fig-0057" title="">Analysis 10.5</a>). Data from two studies found a reduction in treatment failure (RR 0.46, 95% CI 0.27 to 0.79; I<sup>2</sup> = 81%; 165 infants) from use of morphine (<a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported no infant with a seizure or adverse event in either group (90 infants). <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a> reported no difference in days treatment (MD ‐4.00, 95% CI ‐15.59 to 7.59; 75 infants). </p> </li> <li> <p>morphine versus chlorpromazine (<a href="./references#CD002059-fig-0053" title="">Analysis 10.1</a>; <a href="./references#CD002059-fig-0054" title="">Analysis 10.2</a>; <a href="./references#CD002059-fig-0057" title="">Analysis 10.5</a>). <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported a reduction in treatment failure (RR 0.05, 95% CI 0.01 to 0.36; 96 infants) from use of morphine, and no infant with a seizure or adverse event in either group (96 infants). </p> </li> </ol> </li> </ol> </p> </section> <section id="CD002059-sec-0111"> <h4 class="title">Other comparisons</h4> <p> <ol id="CD002059-list-0025"> <li> <p>No study reported tincture of opium.</p> </li> <li> <p>No study compared early versus delayed treatment of NAS, or short versus long courses of therapy for NAS. </p> </li> </ol> </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002059-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002059-sec-0112"></div> <section id="CD002059-sec-0113"> <h3 class="title" id="CD002059-sec-0113">Summary of main results</h3> <section id="CD002059-sec-0114"> <h4 class="title">Opioid versus no treatment / usual care</h4> <p>There was very low certainty evidence, from a single small trial of morphine and supportive care versus supportive care alone, reporting outcomes of 80 infants, of no difference in treatment failure. No infant was reported to have had a seizure. Neonatal or infant mortality, neurodevelopmental disability and adverse events were not reported. There was very low certainty evidence that morphine use increased duration of hospitalisation and days treatment, but reduced days to regain birthweight and duration of supportive care. Data for severity and duration of withdrawal were not available. </p> </section> <section id="CD002059-sec-0115"> <h4 class="title">Morphine versus methadone</h4> <p>There was low certainty evidence, from two studies reporting outcomes of 147 infants, of no difference in treatment failure in infants treated with morphine compared to methadone. Seizures, neonatal or infant mortality and neurodevelopmental disability were not reported. A single study (116 infants) reported no difference in days hospitalisation, whereas data from both studies found an average increase of 2.7 days treatment for infants treated with morphine compared to methadone (low certainty evidence). A single study reported no difference in exclusive or partial breastfeeding, weight gain, adverse events, or out of home placement. Bayley III composite, language or motor scores were not different at 18 months age (83 infants reported). </p> </section> <section id="CD002059-sec-0116"> <h4 class="title">Morphine versus sublingual buprenorphine</h4> <p>There was very low certainty evidence, from three studies reporting outcomes of 113 infants, of no difference in treatment failure or seizures from use of oral morphine versus sublingual buprenorphine. Neonatal or infant mortality and neurodevelopmental disability were not reported. There was moderate certainty evidence of an average increase of 11 days hospitalisation and 13 days treatment for infants treated with morphine compared to sublingual buprenorphine. A single adverse event (seizure) was reported in infants exposed to buprenorphine. </p> </section> <section id="CD002059-sec-0117"> <h4 class="title">Morphine versus diluted tincture of opium</h4> <p>There was low certainty evidence, from a single small study reporting outcomes of 33 infants, of no difference in days hospitalisation, days treatment or weight gain for infants treated with morphine compared to diluted tincture of opium. We were unable to extract data for other outcomes. </p> <p>No studies reported the following opioid comparisons: morphine versus paregoric; diluted tincture of opium versus paregoric; methadone versus buprenorphine; methadone versus paregoric; or paregoric versus buprenorphine. </p> </section> <section id="CD002059-sec-0118"> <h4 class="title">Opioid versus clonidine</h4> <p>A single small study (31 infants) comparing infants treated with morphine versus clonidine reported no infant with treatment failure in either group. Seizures, neonatal or infant mortality and neurodevelopmental disability were not reported. There was low certainty evidence of no difference in days hospitalisation or days treatment. No differences in Bayley III cognitive or motor score and growth parameters at 12 months were reported for 24 infants. Adverse events were not reported. </p> </section> <section id="CD002059-sec-0119"> <h4 class="title">Opioid versus diazepam</h4> <p>There was low certainty evidence, from two studies (86 infants) of an opioid compared to diazepam, of a reduction in treatment failure from use of an opioid. The test for subgroup differences according to type of opioid used (paregoric or methadone) was not significant. Seizures, neonatal or infant mortality and neurodevelopmental disability were not reported. There was very low certainty evidence, from a single study (34 infants) of methadone versus diazepam, of no difference in days hospitalisation or days treatment. Adverse events were not reported. </p> </section> <section id="CD002059-sec-0120"> <h4 class="title">Opioid versus phenobarbital</h4> <p>There was moderate certainty evidence from data extracted from six studies (458 infants) of a reduction in treatment failure (RD ‐0.11, 95% CI ‐0.18 to ‐0.03; number needed to treat to for an additional beneficial outcome (NNTB) 9, 95% CI 6 to 33) from use of an opioid versus phenobarbital. The test for subgroup differences according to type of opioid used was not significant. In subgroup analysis according to dose of morphine used, data from three studies titrating morphine to 0.5 mg/kg/day or more found a reduction in treatment failure, whereas a single study of morphine &lt; 0.5 mg/kg/day reported no difference. The test for subgroup differences was borderline significant (P = 0.05, I<sup>2</sup> = 73.5%). Neonatal or infant mortality and neurodevelopmental disability were not reported. A single study (111 infants) of paregoric versus phenobarbital reported seven infants with seizures (RD ‐0.11, 95% CI ‐0.20 to ‐0.03), all in the phenobarbital group. No seizures were reported in two studies (164 infants) comparing morphine to phenobarbital. There was low to very low certainty evidence of no difference between groups in days hospitalisation (3 studies, 166 infants) or days treatment (6 studies, 348 infants). A single study (90 infants) reported no adverse events in either group (low certainty evidence). </p> </section> <section id="CD002059-sec-0121"> <h4 class="title">Opioid versus chlorpromazine</h4> <p>There was moderate certainty evidence from a single study (96 infants) of a decrease in treatment failure (RD ‐0.43, 95% CI ‐0.57 to ‐0.29; NNTB 2.3, 95% CI 1.8 to 3.4) from use of morphine versus chlorpromazine. No seizures were reported in either group. There was low certainty evidence for no difference between groups in days treatment. No adverse events were reported in either group. </p> </section> </section> <section id="CD002059-sec-0122"> <h3 class="title" id="CD002059-sec-0122">Overall completeness and applicability of evidence</h3> <p>This review includes 16 trials enrolling 1110 infants with NAS secondary to maternal opioid use in pregnancy. Three studies comparing oral morphine to sublingual buprenorphine enrolled infants of mothers using only opioids in pregnancy. Another single study reported infants of mothers using only opioids separately from infants of mothers using opioids and other drugs. All other studies included infants of women using other drugs in addition to an opioid, although a single study excluded infants exposed to benzodiazepines. For comparisons other than oral morphine versus sublingual buprenorphine, there were limited data differentiating infants exposed to opioids alone and infants exposed to an opioid and another drug, so data are applicable to populations with high rates of polydrug use. Most studies were conducted in high‐income counties, with one each in Australia, Germany, Scotland and Switzerland, and 11 in the USA. One study comparing morphine to phenobarbital was conducted in Iran. The majority of studies used a validated NAS scoring system to determine eligibility for treatment: two studies used the Lipsitz score; 12 studies used the Neonatal Abstinence Scoring System (Finnegan score) or a modification thereof; one study used the MOTHER NAS scale; and a single study of morphine versus methadone did not use a formal NAS scoring system but used clinical decision to treat. Fourteen studies titrated pharmacological treatment to a NAS score, a single study of methadone versus phenobarbital versus diazepam titrated dose to clinical response without a formal score, and a single study comparing morphine to phenobarbital did not titrate dose of treatment according to severity of withdrawal. A single study of morphine versus phenobarbital monitored phenobarbital levels and titrated phenobarbital dose to scores and limited increases to a level below 70 μg/mL (<a href="./references#CD002059-bbs2-0005" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984</a>). All other studies titrated sedatives to NAS score without documented use of therapeutic monitoring. </p> <p>Currently, there is not a single agreed validated NAS scoring system. Each scoring tool is prone to challenges of interrater reliability because each contains clinical signs that can be subjective or related to infant adaptation to extrauterine life (<a href="./references#CD002059-bbs2-0138" title="PatrickSW , BarfieldWD , PoindexterBB , AAP Committee on Fetus and Newborn, Committee on Substance Use and Prevention. Neonatal Opioid Withdrawal Syndrome. Pediatrics2020;146(5):e2020029074. [DOI: 10.1542/peds.2020-029074]">Patrick 2020</a>). Outcomes reported in this review, including treatment failure and time to control of NAS, may be affected by use of incompletely validated and accurate scoring systems. </p> <p>Overall, outcomes have been incompletely reported for all comparisons. Neurodevelopmental disability was not reported for any comparison. A single study (83 infants) of morphine versus methadone reported Bayley III scores at 18 months of age, and a single study of morphine versus clonidine reported Bayley III scores at 12 months of age. There is insufficient evidence to determine longer‐term effects of opioids for NAS on longer‐term growth and development. </p> <p>A single study compared morphine and supportive care versus supportive care alone. Supportive care included use of a pacifier, swaddling, close wrapping, small frequent feeds, close skin contact by carrying in a sling and other methods. Other studies did not report specifics of usual or supportive care in sufficient detail to allow for subgroup analysis according to type(s) of non‐pharmacological care as prespecified. For a Cochrane Review of non‐pharmacological care for opioid withdrawal in newborns, see <a href="./references#CD002059-bbs2-0135" title="PahlA , YoungL , Buus‐FrankME , MarcellusL , SollR . Non‐pharmacological care for opioid withdrawal in newborns. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD013217. [DOI: 10.1002/14651858.CD013217.pub2]">Pahl 2020</a>. The study (80 infants) that compared morphine and supportive care versus supportive care alone reported treatment failure, duration of hospitalisation and duration of treatment, but did not report mortality and adverse events. </p> <p>Six studies compared different opioids. Two studies (147 infants) compared morphine to methadone and reported treatment failure, days hospitalisation and treatment, breastfeeding, weight gain, adverse events, out of home placement and Bayley III scores at 18 months old. The three studies (113 infants) compared oral morphine to sublingual buprenorphine, with an increased buprenorphine dose in the latter two studies (<a href="./references#CD002059-bbs2-0010" title="KraftW , DysartK , GibsonE , GreenspanJ , DamleV , KaltenbachK , et al. First use of sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting. 2008, May 2 to 6; Honolulu, Hawaii. 2008:5834.5. KraftWK , GibsonE , DysartK , DamleVS , LarussoJL , GreenspanJS , et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics2008;122(3):e601-7. [DOI: 10.1542/peds.2008-0571] [PMID: 18694901]">Kraft 2008</a>; <a href="./references#CD002059-bbs2-0011" title="KraftWK , DysartK , GreenspanJS , GibsonE , KaltenbachK , EhrlichME . Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction2011;106(3):574-580. [DOI: 10.1111/j.1360-0443.2010.03170.x] [PMID: 20925688]">Kraft 2011</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>). Outcomes reported were limited to treatment failure, seizures, days hospitalisation and treatment, and adverse events. A single study (33 infants) compared morphine to dilute tincture of opium with reporting of outcomes limited to duration of hospitalisation, duration of treatment and weight gain. </p> <p>Eight studies compared an opioid to a sedative. A single study (31 infants) compared morphine to clonidine with reporting including treatment failure, duration of hospitalisation and treatment, growth parameters and Bayley III scores at 12 months of age. Two studies (86 infants) compared an opioid to diazepam with treatment failure reported by both studies. Seizures, neonatal or infant mortality, neurodevelopmental disability and adverse events were not reported by these studies, although one study (34 infants) comparing methadone to diazepam reported duration of hospitalisation and treatment. Six studies (458 infants) compared an opioid to phenobarbital with all studies reporting treatment failure, enabling subgroup analysis according to type of opioid and morphine dosage. Neonatal or infant mortality and neurodevelopmental disability were not reported. Three studies (291 infants) reported seizures; three studies (166 infants) reported duration of hospitalisation; six studies (349 infants) reported duration of treatment; and a single study (96 infants) reported adverse events. </p> <p>Five studies compared paregoric to another opioid or a sedative. Paregoric has been variably compounded to contain excipients, including anise oil, benzoic acid, camphor and alcohol. Additionally, tincture of opium contains about 30 different alkaloids (codeine, noscapine, etc.) with opioid‐like activity. The buprenorphine formulation used in trials included in this Cochrane Review (0.075 mg/mL, containing 30% ethanol, 0.016 mg/kg/day) results in ethanol exposure above the ethanol threshold defined by the European Medicines Agency (<a href="./references#CD002059-bbs2-0093" title="European Medicines Agency Committee for Medicinal Products for Human Use. Information for the package leaflet regarding ethanol used as an excipient in medicinal products for human use; September 2018. Available at ema.europa.eu/en/documents/scientific-guideline/information-package-leaflet-regarding-ethanol-used-excipient-medicinal-products-human-use_en.pdf.">EMA 2018</a>; <a href="./references#CD002059-bbs2-0094" title="European Paediatric Formulation Initiative. STEP database: Safety and Toxicity of Excipients for Paediatrics. www.step-db.ucl.ac.uk/eupfi/appDirectLink.do?appFlag=login (accessed 26 September 2020).">EUPFI 2020</a>; <a href="./references#CD002059-bbs2-0156" title="ValeurKS , HolstH , AllegaertK . Excipients in neonatal medicinal products: never prescribed, commonly administered. Pharmaceutical Medicine2018;32(4):251-8. [DOI: 10.1007/s40290-018-0243-9] [PMID: 30174435]">Valeur 2018</a>). The World Health Organization's development of paediatric medicines' formulation guidance is for the elimination or smallest possible amount of ethanol in paediatric formulations, recognising issues may arise in replacement formulations. Children, especially under the age of six years, are more vulnerable to the effects of ethanol. Adverse effects on the central nervous system are evident at blood ethanol concentrations of 10 mg/100 mL in children. Chronic exposure to ethanol (more than one week), even to small doses, in principle is contraindicated in children aged less than six years and should be limited to two weeks in children aged over six years, if a positive risk–benefit balance is not demonstrated (<a href="./references#CD002059-bbs2-0162" title="World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations. Annex 5 Development of paediatric medicines: points to consider in formulation; WHO Technical Report Series No. 970; 2012. Available at www.who.int/medicines/areas/quality_safety/quality_assurance/Annex5TRS-970.pdf?ua=1;.">WHO 2012</a>). </p> <p>We prespecified the secondary outcome 'time to control of NAS (control of symptoms or reduction of NAS score to a clinically 'safe' level).' Although the majority of studies used a NAS scoring system, severity of withdrawal from initiation of treatment was mostly unreported and no data were extractable for this outcome. A study of morphine versus clonidine reported no difference in Finnegan scores at 48 hours, 7 days and 14 days (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>). A study of paregoric versus phenobarbital reported no difference in Lipsitz scores for all except the 21‐day time point for infants on treatment over a 30‐day period (<a href="./references#CD002059-bbs2-0008" title="KandallSR , DoberczakTM , MauerKR , StrashunRH , KortsDC . Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. American Journal of Diseases of Children1983;137(4):378-82. [DOI: 10.1001/archpedi.1983.02140300056015] [PMID: 6829517]">Kandall 1983</a>). A study of morphine versus diluted tincture of opium reported no difference in Finnegan mean score, maximum score, days with mean score above 8, and area under the curve for score above 8. In this Cochrane Review, 'treatment failure' is a surrogate for control of NAS symptoms (<a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>). </p> <p>This Cochrane Review is limited to the comparisons above. For comparisons of sedatives to no treatment or usual care, and sedatives to other sedatives, see the Cochrane Review, 'Sedatives for opioid withdrawal in newborn infants' (<a href="./references#CD002059-bbs2-0167" title="ZanklA , MartinJ , DaveyJG , OsbornDA . Sedatives for opioid withdrawal in newborn infants. Cochrane Database of Systematic Reviews2021;(in press).">Zankl 2021</a>). No randomised trial of opioid versus dexmedetomidine was found. </p> <p>There were no comparisons of different dosage regimens of opioids. Data for subgroup analysis according to dosage used were limited to the comparison morphine versus phenobarbital for the outcome of treatment failure (morphine ≥ 0.5 mg/kg/day versus &lt; 0.5 mg/kg/day) due to insufficient studies available for subgroup analysis for other comparisons and outcomes. Dosage regimens are reported in <a href="./references#CD002059-sec-0154" title="">Characteristics of included studies</a>. </p> <p>There were no trials comparing pharmacological approaches with specific non‐pharmacological approaches of care for infants with NAS including the ESC approach. </p> </section> <section id="CD002059-sec-0123"> <h3 class="title" id="CD002059-sec-0123">Quality of the evidence</h3> <p>There was low or very low certainty of evidence for the majority of comparisons and outcomes reported in this review, with downgrading frequent for serious risk of bias and imprecision. The review is limited to 16 studies reporting 1110 infants with NAS secondary to maternal opioid use in pregnancy across multiple comparisons of different opioids, supportive care and different sedatives. Therefore, analyses are largely underpowered to detect important differences, particularly for outcomes of lower incidence, including seizures and treatment‐related adverse effects. We considered seven studies to be at low risk of bias (adequate randomisation and allocation concealment, blinding of treatment and greater than 90% follow up) (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>; <a href="./references#CD002059-bbs2-0002" title="BrownMS , HayesMJ , ThorntonLM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. Journal of Perinatology2015;35(4):278-83. [DOI: 10.1038/jp.2014.194] [NCT01804075] [PMID: 25357093]NCT01804075. Comparison between methadone and morphine for neonatal opiate withdrawal [Evaluation of efficacy of methadone versus morphine for treatment of neonatal abstinence syndrome (NAS)]. clinicaltrialsgov/show/NCT01804075 (first received 5 March 2013). ">Brown 2015</a>; <a href="./references#CD002059-bbs2-0004" title="CzynskiA , DavisJ , ShenbergerJ , TerrinN , BreezeJ , HudakM , et al. Neonatal neurobehavioral effects following treatment for Neonatal Abstinence Syndrome (NAS) using morphine vs methadone. In: Pediatric Academic Societies 2018 Meeting. May 5 – 8, 2018, Toronto Canada. 2018. CzynskiAJ , DavisJM , DansereauLM , EngelhardtB , MarroP , BogenDL , et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. Journal of Pediatrics2020;219:146-51. [DOI: 10.1016/j.jpeds.2019.12.018] [PMID: 31987653]DavisJ , ShenbergerJ , TerrinN , BreezeJ , Harvey-WilkesK , HudakM , et al. Morphine vs. methadone for the treatment of neonatal abstinence syndrome (NAS). In: Pediatric Academic Societies Meeting. 2018, May 5-8; Toronto Canada. 2018. DavisJM , ShenbergerJ , TerrinN , BreezeJL , HudakM , WachmanEM , et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatrics2018;172(8):741-8. [DOI: 10.1001/jamapediatrics.2018.1307] [PMID: 29913015]FlanneryT , DavisJM , CzynskiAJ , DansereauLM , OliveiraEL , CamardoSA , et al. Neonatal abstinence syndrome severity index predicts 18 month neurodevelopmental outcome in neonates randomized to morphine or methadone. Journal of Pediatrics2020;227:101-7.e1. [DOI: 10.1016/j.jpeds.2020.08.034] [PMID: 32805259]NCT01958476. Improving outcomes in neonatal abstinence syndrome. clinicaltrialsgov/show/NCT01958476 (first received 9 Octover 2013). ">Davis 2018</a>; <a href="./references#CD002059-bbs2-0006" title="JacksonL , TingA , McKayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(4):F300-4. [DOI: 10.1136/adc.2003.033555] [PMID: 15210660]">Jackson 2004</a>; <a href="./references#CD002059-bbs2-0012" title="KraftWK , Adeniyi-JonesSC , ChervonevaI , GreenspanJS , AbatemarcoD , KaltenbachK , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New England Journal of Medicine2017;376(24):2341-8. [DOI: 10.1056/NEJMoa1614835] [PMID: 28468518]MooreJN , GastonguayMR , NgCM , Adeniyi-JonesSC , MoodyDE , FangWB , et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clinical Pharmacology and Therapeutics2018;103(6):1029-37. [DOI: 10.1002/cpt.1064] [PMID: 29516490]NCT01452789. Blinded trial of buprenorphine or morphine in the treatment of the neonatal abstinence syndrome [A randomized, active-control, double-blind, double-dummy clinical trial comparing sublingual buprenorphine and morphine solution for the treatment of neonatal opioid abstinence syndrome]. clinicaltrialsgov/show/NCT01452789 (first received 17 October 2011). ">Kraft 2017</a>; <a href="./references#CD002059-bbs2-0013" title="LangenfeldS , BirkenfeldL , HerkenrathP , MullerC , HellmichM , TheisohnM . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Dependence2005;77(1):31-6. [DOI: 10.1016/j.drugalcdep.2004.07.001] [PMID: 15607839]">Langenfeld 2005</a>; <a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>), although two studies had complete reporting only for short‐term outcomes (<a href="./references#CD002059-bbs2-0001" title="BadaH , SithisarnT , CaldwellR , GibsonJ , WhiteheadV , GriderD , et al. Clonidine as a single drug therapy in neonatal abstinence: a pilot study. In: American Federation for Medical Research Southern Regional Meeting Abstracts; 2014 February 20-22; New Orleans, Louisiana. 2014:573. BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]NCT01734551. NAS Treatment - opiate versus non-opiate [Pharmacological treatment of neonatal abstinence syndrome: opiate versus non-opiate]. clinicaltrials.gov/ct2/show/NCT01734551 (first received 27 November 2012). ">Bada 2015</a>), and for treatment failure, seizures and adverse events (<a href="./references#CD002059-bbs2-0016" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). Sensitivity analysis identified a significant reduction in treatment failure in analysis of two studies (171 infants) of morphine versus phenobarbital, and a single study reported an increase in days hospitalisation and days treatment for infants treated with morphine versus buprenorphine. </p> <p>Moderate certainty of evidence was limited to: data from three studies which found an increase in duration of hospitalisation and duration of treatment for infants treated with morphine compared to sublingual buprenorphine; data from six studies which found a reduction in treatment failure for infants treated with an opioid versus phenobarbital; and data from a single study (90 infants) which reported a reduction in treatment failure for infants treated with morphine versus chlorpromazine. </p> </section> <section id="CD002059-sec-0124"> <h3 class="title" id="CD002059-sec-0124">Potential biases in the review process</h3> <p>We performed an extensive search for published and unpublished studies in an attempt to avoid publication bias. However, we did not perform searches of non‐English databases. At least two review authors independently screened studies for eligibility, performed risk of bias assessment and extracted data. The review included studies using quasi‐random participant allocation, increasing the risk of selection bias in the studies included in the review. We have addressed this using sensitivity analysis and GRADE. We prespecified the primary outcomes and the comparisons that were made. </p> </section> <section id="CD002059-sec-0125"> <h3 class="title" id="CD002059-sec-0125">Agreements and disagreements with other studies or reviews</h3> <p>Several recent reviews have assessed the evidence for different pharmacological and non‐pharmacological treatments for infants with NAS (<a href="./references#CD002059-bbs2-0092" title="DisherT , GullicksonC , SinghB , CameronC , BoulosL , BeaubienL , et al. Pharmacological treatments for neonatal abstinence syndrome: a systematic review and network meta-analysis. JAMA Pediatrics2019;173(3):234-43. [DOI: 10.1001/jamapediatrics.2018.5044] [PMID: 30667476]">Disher 2019</a>; <a href="./references#CD002059-bbs2-0119" title="LeeJJ , ChenJ , EislerL , LiG , DavisJM , SunLS . Comparative effectiveness of opioid replacement agents for neonatal opioid withdrawal syndrome: a systematic review and meta-analysis. Journal of Perinatology2019;39(11):1535-45. [DOI: 10.1038/s41372-019-0437-3] [PMID: 31316147]">Lee 2019</a>; <a href="./references#CD002059-bbs2-0122" title="MacMillanKD , RendonCP , VermaK , RibletN , WasherDB , HolmesAV . Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatrics2018;172(4):345-51. [DOI: 10.1001/jamapediatrics.2017.5195] [PMID: 29404599]">MacMillan 2018</a>; <a href="./references#CD002059-bbs2-0135" title="PahlA , YoungL , Buus‐FrankME , MarcellusL , SollR . Non‐pharmacological care for opioid withdrawal in newborns. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD013217. [DOI: 10.1002/14651858.CD013217.pub2]">Pahl 2020</a>; <a href="./references#CD002059-bbs2-0165" title="XiaoF , YanK , ZhouW . Methadone versus morphine treatment outcomes in neonatal abstinence syndrome: a meta-analysis. Journal of Paediatrics and Child Health2019;55:1177-82. [DOI: 10.1111/jpc.14609] [PMID: 31479559]">Xiao 2019</a>). </p> <p>A systematic review and network meta‐analysis of pharmacological treatments for neonatal abstinence syndrome included 18 trials with 1072 infants (<a href="./references#CD002059-bbs2-0092" title="DisherT , GullicksonC , SinghB , CameronC , BoulosL , BeaubienL , et al. Pharmacological treatments for neonatal abstinence syndrome: a systematic review and network meta-analysis. JAMA Pediatrics2019;173(3):234-43. [DOI: 10.1001/jamapediatrics.2018.5044] [PMID: 30667476]">Disher 2019</a>). Sublingual buprenorphine was considered the optimal treatment for a reduction in the length of treatment and length of stay, but not the need for adjuvant treatment. The results were robust to bias but sensitive to imprecision. Disher and colleagues concluded that the current evidence suggests that buprenorphine is the optimal treatment for neonatal abstinence syndrome, but limitations are considerable and wide‐scale adoption requires a large, multisite trial. Morphine, which is considered standard of care in most hospitals, was the lowest‐ranked opioid for length of treatment and length of stay. The finding of this systematic review and network meta‐analysis are compatible with our review of direct comparisons. However, the conclusions of <a href="./references#CD002059-bbs2-0092" title="DisherT , GullicksonC , SinghB , CameronC , BoulosL , BeaubienL , et al. Pharmacological treatments for neonatal abstinence syndrome: a systematic review and network meta-analysis. JAMA Pediatrics2019;173(3):234-43. [DOI: 10.1001/jamapediatrics.2018.5044] [PMID: 30667476]">Disher 2019</a> are strongly influenced by the network meta‐analysis which includes rankings derived from direct and indirect effects, and which is sensitive to imprecision due to the relatively small number of infants included in any comparison. In addition, outcomes were of surrogates of treatment effect, including length of treatment, length of stay, need for adjuvant treatment and discontinuation of treatment for adverse events. </p> <p>A systematic review of RCTs and observational studies assessing the short‐term treatment outcomes of opioid pharmacotherapy for neonatal opioid withdrawal syndrome found methadone increased treatment success compared with morphine, and buprenorphine was associated with the shortest overall durations of treatment and hospitalisation (<a href="./references#CD002059-bbs2-0119" title="LeeJJ , ChenJ , EislerL , LiG , DavisJM , SunLS . Comparative effectiveness of opioid replacement agents for neonatal opioid withdrawal syndrome: a systematic review and meta-analysis. Journal of Perinatology2019;39(11):1535-45. [DOI: 10.1038/s41372-019-0437-3] [PMID: 31316147]">Lee 2019</a>). These conclusions should be treated with caution as the review is potentially biased by the inclusion of observational studies. </p> <p>A systematic review of RCTs and observational studies reviewed the evidence for rooming‐in for infants with NAS (<a href="./references#CD002059-bbs2-0122" title="MacMillanKD , RendonCP , VermaK , RibletN , WasherDB , HolmesAV . Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatrics2018;172(4):345-51. [DOI: 10.1001/jamapediatrics.2017.5195] [PMID: 29404599]">MacMillan 2018</a>). No RCTs were found. Review of six before‐and‐after studies found opioid‐exposed newborns rooming‐in with mother or other family members appear to be significantly less likely to be treated with pharmacotherapy and have substantial reductions in length of stay compared with those cared for in NICUs. The conclusions should be treated with caution as the review is potentially biased by the inclusion of observational studies. </p> <p>A review of RCTs and observational studies of morphine versus methadone treatment for NAS found no significant difference in treatment days, length of hospital stay and duration of treatment between morphine or methadone treatment (<a href="./references#CD002059-bbs2-0123" title="MangatAK , SchmolzerGM , KraftWK . Pharmacological and non-pharmacological treatments for the neonatal abstinence syndrome (NAS). Seminars in Fetal and Neonatal Medicine2019;24(2):133-41. [DOI: 10.1016/j.siny.2019.01.009] [PMID: 30745219]">Mangat 2019</a>). Although the conclusions should be treated with caution as the review is potentially biased by the inclusion of observational studies, the conclusions are consistent with our review. </p> <p>The Cochrane Review, 'Non‐pharmacological care for opioid withdrawal in newborns' (<a href="./references#CD002059-bbs2-0135" title="PahlA , YoungL , Buus‐FrankME , MarcellusL , SollR . Non‐pharmacological care for opioid withdrawal in newborns. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD013217. [DOI: 10.1002/14651858.CD013217.pub2]">Pahl 2020</a>), found uncertain evidence from six included studies for whether non‐pharmacological care for opioid withdrawal in newborns affects important clinical outcomes, including length of hospitalisation and use of pharmacological treatment. The review did not include <a href="./references#CD002059-bbs2-0009" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne, AU: Department of Psychology, University of Melbourne, 1995. [minerva-access.unimelb.edu.au/handle/11343/38959]">Khoo 1995</a>, a study included in our review which compared morphine plus supportive care, phenobarbital plus supportive care to supportive care alone. </p> <p>Together with our two reviews of pharmacological interventions (this review and the Cochrane Review, 'Sedatives for opioid withdrawal in newborn infants' (<a href="./references#CD002059-bbs2-0167" title="ZanklA , MartinJ , DaveyJG , OsbornDA . Sedatives for opioid withdrawal in newborn infants. Cochrane Database of Systematic Reviews2021;(in press).">Zankl 2021</a>)), the reviews discussed above indicate that further well‐designed, appropriately powered studies are needed to determine the effects of both non‐pharmacological and pharmacological care for opioid withdrawal in newborns. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002059-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update 2020" data-id="CD002059-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update 2020</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Screen4Me summary diagram" data-id="CD002059-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Screen4Me summary diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD002059-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 1: Treatment failure" data-id="CD002059-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 2: Seizures" data-id="CD002059-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 2: Seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 3: Days hospitalisation" data-id="CD002059-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 3: Days hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 4: Days treatment" data-id="CD002059-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 4: Days treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 5: Days to regain birth weight" data-id="CD002059-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 5: Days to regain birth weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 6: Days in special care nursery" data-id="CD002059-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 6: Days in special care nursery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 7: Duration supportive care (minutes/day)" data-id="CD002059-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Opioid versus placebo or no treatment / usual care (all infants), Outcome 7: Duration supportive care (minutes/day) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 1: Treatment failure" data-id="CD002059-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 2: Seizures" data-id="CD002059-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 2: Seizures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 3: Days hospitalisation" data-id="CD002059-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 3: Days hospitalisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 4: Days treatment" data-id="CD002059-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 4: Days treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 5: Exclusive or partially breastfed" data-id="CD002059-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 5: Exclusive or partially breastfed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 6: Weight gain (g/day)" data-id="CD002059-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 6: Weight gain (g/day)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 7: Adverse events (treatment related)" data-id="CD002059-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 7: Adverse events (treatment related) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 8: Out of home placement" data-id="CD002059-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 8: Out of home placement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 9: Bayley III cognitive composite score at 18 months" data-id="CD002059-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 9: Bayley III cognitive composite score at 18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 10: Bayley III language composite score at 18 months" data-id="CD002059-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 10: Bayley III language composite score at 18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Opioid versus other opioid (all infants), Outcome 11: Bayley III motor composite score at 18 months" data-id="CD002059-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Opioid versus other opioid (all infants), Outcome 11: Bayley III motor composite score at 18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Opioid versus other opioid (infants of mothers using only opioids), Outcome 1: Treatment failure" data-id="CD002059-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Opioid versus other opioid (infants of mothers using only opioids), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Opioid versus other opioid (infants of mothers using only opioids), Outcome 2: Seizures" data-id="CD002059-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Opioid versus other opioid (infants of mothers using only opioids), Outcome 2: Seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Opioid versus other opioid (infants of mothers using only opioids), Outcome 3: Days hospitalisation" data-id="CD002059-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Opioid versus other opioid (infants of mothers using only opioids), Outcome 3: Days hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Opioid versus other opioid (infants of mothers using only opioids), Outcome 4: Days treatment" data-id="CD002059-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Opioid versus other opioid (infants of mothers using only opioids), Outcome 4: Days treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Opioid versus clonidine (all infants), Outcome 1: Treatment failure" data-id="CD002059-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Opioid versus clonidine (all infants), Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Opioid versus clonidine (all infants), Outcome 2: Days hospitalisation" data-id="CD002059-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Opioid versus clonidine (all infants), Outcome 2: Days hospitalisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Opioid versus clonidine (all infants), Outcome 3: Days treatment" data-id="CD002059-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Opioid versus clonidine (all infants), Outcome 3: Days treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Opioid versus clonidine (all infants), Outcome 4: Weight (kg) at 12 months" data-id="CD002059-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Opioid versus clonidine (all infants), Outcome 4: Weight (kg) at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Opioid versus clonidine (all infants), Outcome 5: Length (cm) at 12 months" data-id="CD002059-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Opioid versus clonidine (all infants), Outcome 5: Length (cm) at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Opioid versus clonidine (all infants), Outcome 6: Head circumference (cm) at 12 months" data-id="CD002059-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Opioid versus clonidine (all infants), Outcome 6: Head circumference (cm) at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Opioid versus clonidine (all infants), Outcome 7: Bayley III cognitive score at 12 months" data-id="CD002059-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Opioid versus clonidine (all infants), Outcome 7: Bayley III cognitive score at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Opioid versus clonidine (all infants), Outcome 8: Bayley III motor score at 12 months" data-id="CD002059-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Opioid versus clonidine (all infants), Outcome 8: Bayley III motor score at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Opioid versus diazepam (all infants), Outcome 1: Treatment failure" data-id="CD002059-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Opioid versus diazepam (all infants), Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Opioid versus diazepam (all infants), Outcome 2: Days hospitalisation" data-id="CD002059-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Opioid versus diazepam (all infants), Outcome 2: Days hospitalisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Opioid versus diazepam (all infants), Outcome 3: Days treatment" data-id="CD002059-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Opioid versus diazepam (all infants), Outcome 3: Days treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Opioid versus diazepam (infants of mothers using only opioids), Outcome 1: Treatment failure" data-id="CD002059-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Opioid versus diazepam (infants of mothers using only opioids), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 1: Treatment failure" data-id="CD002059-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 2: Treatment failure ‐ higher versus lower maximal dose of opioid" data-id="CD002059-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 2: Treatment failure ‐ higher versus lower maximal dose of opioid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 3: Seizures" data-id="CD002059-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 3: Seizures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 4: Days hospitalisation" data-id="CD002059-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 4: Days hospitalisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 5: Days treatment" data-id="CD002059-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 5: Days treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 6: Days to regain birth weight" data-id="CD002059-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 6: Days to regain birth weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 7: Adverse events (treatment related)" data-id="CD002059-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 7: Adverse events (treatment related) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 8: Admission to nursery" data-id="CD002059-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 8: Admission to nursery</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 9: Days in special care nursery" data-id="CD002059-fig-0046" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 9: Days in special care nursery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-007.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid versus phenobarbital (all infants), Outcome 10: Duration supportive care (minutes/day)" data-id="CD002059-fig-0047" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-007.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7: Opioid versus phenobarbital (all infants), Outcome 10: Duration supportive care (minutes/day) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-007.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Opioid versus phenobarbital (infants of mothers using only opioids), Outcome 1: Treatment failure" data-id="CD002059-fig-0048" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Opioid versus phenobarbital (infants of mothers using only opioids), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Opioid versus chlorpromazine (all infants), Outcome 1: Treatment failure" data-id="CD002059-fig-0049" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Opioid versus chlorpromazine (all infants), Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Opioid versus chlorpromazine (all infants), Outcome 2: Seizures" data-id="CD002059-fig-0050" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Opioid versus chlorpromazine (all infants), Outcome 2: Seizures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Opioid versus chlorpromazine (all infants), Outcome 3: Days treatment" data-id="CD002059-fig-0051" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Opioid versus chlorpromazine (all infants), Outcome 3: Days treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Opioid versus chlorpromazine (all infants), Outcome 4: Adverse events (treatment related)" data-id="CD002059-fig-0052" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Opioid versus chlorpromazine (all infants), Outcome 4: Adverse events (treatment related) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analyses, Outcome 1: Treatment failure" data-id="CD002059-fig-0053" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analyses, Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analyses, Outcome 2: Seizures" data-id="CD002059-fig-0054" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analyses, Outcome 2: Seizures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analyses, Outcome 3: Days hospitalisation" data-id="CD002059-fig-0055" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analyses, Outcome 3: Days hospitalisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analyses, Outcome 4: Days treatment" data-id="CD002059-fig-0056" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analyses, Outcome 4: Days treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002059-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/urn:x-wiley:14651858:media:CD002059:CD002059-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analyses, Outcome 5: Adverse events (treatment related)" data-id="CD002059-fig-0057" src="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_t/tCD002059-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analyses, Outcome 5: Adverse events (treatment related)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/media/CDSR/CD002059/image_n/nCD002059-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002059-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Opioid versus placebo or no treatment / usual care for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus placebo or no treatment / usual care for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, Australia<br/><b>Intervention:</b> opioid versus placebo or no treatment / usual care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine and usual care</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/>(48 to 479) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> <br/>(0.41 to 4.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>14</b> days in the usual care group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>15 higher</b> (8.86 to 21.14 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>8.5</b> days in the usual care group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>12.5 higher</b> (7.52 to 17.48 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment‐related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious risk of bias (quasi‐random allocation, no blinding).<br/><sup>b</sup>Downgraded one level for serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Opioid versus placebo or no treatment / usual care for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002059-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Morphine versus methadone for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morphine versus methadone for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> morphine versus methadone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Methadone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>219 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b><br/>(208 to 585) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.59</b> <br/>(0.95 to 2.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>21.8</b> in the methadone group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>1.4 higher</b> (3.08 lower to 5.88 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>14 to 14.7</b> in the methadone group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>2.71 higher</b> (0.22 to 5.21 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(0 to 138) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 8.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single event only</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals).<br/><sup>b</sup>Downgraded one level for serious inconsistency (moderate heterogeneity: I² = 54%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Morphine versus methadone for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002059-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Morphine versus buprenorphine for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morphine versus buprenorphine for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> morphine versus buprenorphine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine versus buprenorphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b><br/>(74 to 360) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> <br/>(0.36 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buprenorphine dose commenced at 13.2 μg/kg/day with dose titration to a maximum of 39 μg/kg/day in one trial, and commenced at 15.9 μg/kg/day with dose titration to a maximum of 60 μg/kg/day in two trials. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(0 to 129) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 7.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single event only</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>21 to 32</b> in the buprenorphine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>11.45 higher</b> (5.89 to 17.01 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>15 to 23</b> in the buprenorphine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>12.79 higher</b> (7.57 to 18 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment‐related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(0 to 129) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 7.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single event only</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (two studies unblinded).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals).<br/><sup>c</sup>Downgraded one level for serious inconsistency (heterogeneity I² = 42%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Morphine versus buprenorphine for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002059-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Morphine versus dilute tincture of opium for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morphine versus dilute tincture of opium for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, Germany<br/><b>Intervention:</b> morphine versus dilute tincture of opium </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dilute tincture of opium (DTO)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>32.4</b> in the DTO group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>5.1 higher</b> (2.08 lower to 12.28 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>26.9</b> in the DTO group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>2.9 higher</b> (5.22 lower to 11.02 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> (treatment related) </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Morphine versus dilute tincture of opium for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002059-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Opioid versus clonidine for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus clonidine for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> opioid versus clonidine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Clonidine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>14.9</b> in the clonidine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>6.1 higher</b> (0.78 lower to 12.98 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>32</b> in the clonidine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>10.7 higher</b> (2.76 lower to 24.16 higher) in the morphine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals, single small study). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Opioid versus clonidine for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002059-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Opioid versus diazepam for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus diazepam for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> opioid versus diazepam </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Diazepam</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Opioid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b><br/>(89 to 311) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/>(0.23 to 0.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a, b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Differences in study methodology and type of opioid used: one study paregoric versus diazepam; one study methadone versus diazepam. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>16.8</b> in the diazepam group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation was <b>4.38 higher</b> (1.26 lower to 10.02 higher) in the opioid group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methadone versus diazepam</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>10.2</b> in the diazepam group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment was <b>1.56 higher</b> (1.59 lower to 4.71 higher) in the opioid group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methadone versus diazepam</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (high risk allocation procedures, unblinded studies).<br/><sup>b</sup>Downgraded one level for serious inconsistency (heterogeneity I² = 37%).<br/><sup>c</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Opioid versus diazepam for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002059-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Opioid versus phenobarbital for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus phenobarbital for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, Australia, Iran, Switzerland, USA<br/><b>Intervention:</b> opioid versus phenobarbital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Opioid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b><br/>(102 to 215) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b> <br/>(0.35 to 0.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test for subgroup differences according to type of opioid use (morphine, paregoric or methadone) not significant. </p> <p>Subgroup analysis of morphine versus phenobarbital found significant reduction in treatment failure (RR 0.46, 95% CI 0.30 to 0.73; I<sup>2</sup> = 44%; 4 studies, 299 infants). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b><br/>(0 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b> <br/>(0 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b, c, d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study reported seven infants with seizures in phenobarbital group. The other study reported no events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation ranged from <b>12.5 to 34.8</b> in the phenobarbital group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days hospitalisation in the opioid group was <b>0.62 lower</b> (2.97 lower to 1.74 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d, e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment ranged from <b>8.5 to 32</b> in the phenobarbital group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment in the opioid group was <b>1.01 higher</b> (0.48 lower to 2.5 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b, d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d, e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious inconsistency (heterogeneity I² = 32%).<br/><sup>b</sup>Downgraded one level for serious risk of bias (single study at low risk of bias).<br/><sup>c</sup>Downgraded one level for serious inconsistency (one of two studies reported events).<br/><sup>d</sup>Downgraded one level for serious imprecision (wide confidence intervals).<br/><sup>e</sup>Downgraded one level for very serious risk of bias (no study at low risk of bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Opioid versus phenobarbital for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002059-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Opioid versus chlorpromazine for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid versus chlorpromazine for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, Switzerland<br/><b>Intervention:</b> morphine versus chlorpromazine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Chlorpromazine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>277 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(3 to 171) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b> <br/>(0.01 to 0.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal or infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean was 25 days treatment in the chlorpromazine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days treatment in the morphine group was <b>3 lower</b> (15.12 lower to 9.12 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded for serious risk of bias and imprecision.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious imprecision. Single small study.<br/><sup>b</sup>Downgraded two levels for serious imprecision. Single small study with no events.<br/><sup>c</sup>Downgraded two levels for serious risk of attrition bias and imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Opioid versus chlorpromazine for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/full#CD002059-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Opioid versus placebo or no treatment / usual care (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.41, 4.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Morphine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.41, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Morphine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Days hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.00 [8.86, 21.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Morphine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.00 [8.86, 21.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Days treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.50 [7.52, 17.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Morphine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.50 [7.52, 17.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Days to regain birth weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.80 [‐5.33, ‐0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Morphine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.80 [‐5.33, ‐0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Days in special care nursery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.70 [10.67, 22.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Morphine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.70 [10.67, 22.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Duration supportive care (minutes/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐197.20 [‐274.15, ‐120.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Morphine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐197.20 [‐274.15, ‐120.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Opioid versus placebo or no treatment / usual care (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Opioid versus other opioid (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.95, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.36, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Days hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐3.08, 5.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.45 [5.89, 17.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Morphine versus diluted tincture of opium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.10 [‐2.08, 12.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Days treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.22, 5.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.79 [7.57, 18.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Morphine versus diluted tincture of opium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [‐5.22, 11.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Exclusive or partially breastfed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.51, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.51, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Weight gain (g/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [‐2.31, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Morphine versus diluted tincture of opium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [‐6.23, 13.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse events (treatment related) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Out of home placement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.54, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Bayley III cognitive composite score at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐10.31, 6.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Bayley III language composite score at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐9.46, 5.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Bayley III motor composite score at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.30 [‐11.77, 3.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Opioid versus other opioid (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Opioid versus other opioid (infants of mothers using only opioids)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.36, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Days hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.45 [5.89, 17.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Days treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.83 [7.57, 18.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Opioid versus other opioid (infants of mothers using only opioids)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Opioid versus clonidine (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Days hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [‐0.78, 12.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [‐0.78, 12.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Days treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.70 [‐2.76, 24.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.70 [‐2.76, 24.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Weight (kg) at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.53, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.53, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Length (cm) at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.97, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.97, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Head circumference (cm) at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐1.10, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐1.10, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Bayley III cognitive score at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐6.66, 5.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐6.66, 5.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Bayley III motor score at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐5.36, 8.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐5.36, 8.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Opioid versus clonidine (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Opioid versus diazepam (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.23, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Paregoric versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.18, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Methadone versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.12, 61.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Days hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.38 [‐1.26, 10.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Methadone versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.38 [‐1.26, 10.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Days treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [‐1.59, 4.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Methadone versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [‐1.59, 4.71]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Opioid versus diazepam (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Opioid versus diazepam (infants of mothers using only opioids)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.02, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Paregoric versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.02, 0.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Opioid versus diazepam (infants of mothers using only opioids)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Opioid versus phenobarbital (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.41, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.30, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Paregoric versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.53, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 Methadone versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.06, 13.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Treatment failure ‐ higher versus lower maximal dose of opioid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.30, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Morphine ≥ 0.5 mg/kg/day versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.13, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Morphine &lt; 0.5 mg/kg/day versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.42, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 Paregoric versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Days hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐2.97, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐3.18, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.2 Methadone versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐6.37, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Days treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [‐0.48, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐3.07, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.2 Paregoric versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.25 [1.92, 6.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.3 Methadone versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.74 [‐7.81, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Days to regain birth weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐3.47, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐3.47, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Adverse events (treatment related) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Admission to nursery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.27, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.1 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.27, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.9 Days in special care nursery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.40 [‐13.81, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.1 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.40 [‐13.81, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.10 Duration supportive care (minutes/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐35.10 [‐86.87, 16.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10.1 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐35.10 [‐86.87, 16.67]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Opioid versus phenobarbital (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Opioid versus phenobarbital (infants of mothers using only opioids)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Paregoric versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Opioid versus phenobarbital (infants of mothers using only opioids)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Opioid versus chlorpromazine (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Morphine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Morphine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Days treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐15.08, 9.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Morphine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐15.08, 9.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Adverse events (treatment related) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 Morphine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Opioid versus chlorpromazine (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002059-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.95, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.55, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.3 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.4 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.27, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.5 Morphine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.3 Morphine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Days hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐3.08, 5.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.2 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.00 [4.83, 19.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.3 Morphine versus diluted tincture of opium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.10 [‐2.08, 12.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.4 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [‐0.78, 12.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Days treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.22, 5.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.2 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.00 [5.71, 20.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.3 Morphine versus diluted tincture of opium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [‐5.22, 11.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.4 Morphine versus clonidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.70 [‐2.76, 24.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.5 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐15.59, 7.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Adverse events (treatment related) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 Morphine versus methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.2 Morphine versus buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.3 Morphine versus phenobarbital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.4 Morphine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002059.pub4/references#CD002059-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002059.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002059-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002059-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002059-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD002059-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD002059-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002059-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002059\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002059\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002059\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002059\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002059\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002059.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002059.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002059.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002059.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002059.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726862658"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002059.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726862662"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002059.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9e015f68f480',t:'MTc0MDcyNjg2My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 